Nitrogen-containing heteropolycyclic derivative inhibitor, preparation method therefor and use thereof

Abstract

The present invention relates to a nitrogen-containing heteropolycyclic derivative modulator, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of drugs for treating menopausal syndrome, polycystic ovarian syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor symptoms, breast cancer and related disorders thereof, wherein each substituent in general formula (I) is the same as defined in the description.

Description

Nitrogen-containing heterocyclic polycyclic derivative inhibitors, their preparation methods and applications Technical Field

[0001] This invention belongs to the field of pharmaceutical biology, specifically relating to a nitrogen-containing heterocyclic polycyclic derivative inhibitor, its preparation method, and its application. Background Technology

[0002] Neurokinins (NK) comprise substance P (SP), neurokinin A, and neurokinin B, corresponding to three types of receptors: neurokinin 1 receptor (NK1R), neurokinin 2 receptor (NK2R), and neurokinin 3 receptor (NK3R). All three are G protein-coupled receptors. NK1R is the most widely distributed, found in both the central and peripheral nervous systems; NK2R is mainly distributed in the peripheral nervous system; and NK3R is mainly distributed in the central nervous system. Currently, NK receptor inhibitors are used to treat menopausal hot flashes, depression, schizophrenia, and other conditions. In particular, NK3R is closely related to menopausal symptoms such as hot flashes, and NK3R inhibitors have been shown to effectively alleviate menopausal hot flashes.

[0003] Menopausal hot flashes refer to the symptoms of hot flashes and sweating that often occur in women during menopause, and are a prominent manifestation of menopausal syndrome. Menopausal hot flashes are caused by a decline in estrogen levels, leading to vasomotor dysfunction. When estrogen levels drop, the brain mistakenly interprets this as excessively high body temperature. Therefore, the brain signals the heart to pump more blood and the sweat glands to release more sweat, accompanied by sweating, palpitations, and dizziness. More than three-quarters of women experience hot flashes during menopause, and 80% of patients experience these symptoms for more than a year, some even persisting for about five years after menopause. Currently, the main treatment for menopausal hot flashes is hormone replacement therapy, but this therapy carries a high risk of complications such as breast cancer, stroke, coronary heart disease, and dementia.

[0004] Therefore, there is an urgent need to develop highly active NK receptor inhibitors to improve menopausal hot flashes in order to meet the huge market demand. Summary of the Invention

[0005] The object of this invention is to provide a compound of general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof:

[0006] in:

[0007] Selected from single or double bonds;

[0008] X1 or X2 is independently selected from CH, N, O or C(O);

[0009] X3, X4, and X5 are each independently selected from C or N;

[0010] X6 is selected from CH or N;

[0011] Y1 is selected from CH, C(O), N, NH, O, S or does not exist;

[0012] Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S;

[0013] Ring A is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, alkenylcarboxyl, alkynylcarboxyl, or dialkylamino groups;

[0014] L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12 ) m1 -、-O-、-S-、-C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - An aromatic heteroalkyl or heterocyclic group, wherein the aromatic heteroalkyl or heterocyclic group is optionally substituted with one or more substituents selected from oxo, alkyl, alkenyl, alkynyl, halogen, amino, hydroxyl, cyano, nitro, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl.

[0015] R 11 R 12 R 13 or R 14Each of the following groups is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the amino, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups;

[0016] R1, R2, R3, or R4 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, and -(CH2). n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb -(CH2) n1 C(O)NR aa R bb Or -(CH2) n1 N=S(O)R aa R bb The amino, hydroxyl, mercapto, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl groups.

[0017] Alternatively, R1 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 Raa One or more substituents are substituted in the sample;

[0018] Alternatively, R1 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0019] Alternatively, R2 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0020] Alternatively, R3 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0021] Alternatively, the two R3 groups form a cycloalkyl, heterocyclic, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0022] Alternatively, the two R1 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, deuterated alkoxy, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, or -(CH2). n1C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0023] Or, R1, R 11 It forms a cycloalkyl, heterocyclic, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0024] R aa or R bb Each of the following groups is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups, wherein the amino, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, alkylacyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups;

[0025] x, y, or t are each independently 0, 1, 2, 3, or 4;

[0026] z is 0, 1, or 2;

[0027] m1 can be 0, 1, 2, or 3;

[0028] n1 or n2 can be 0, 1, 2 or 3 independently;

[0029] The conditions are:

[0030] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not...

[0031] When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0032] When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0033] In some embodiments of the present invention, a compound of general formula (I-1), its stereoisomer, or a pharmaceutically acceptable salt thereof is provided, the structure of which is as follows:

[0034] in:

[0035] X1 or X2 is independently selected from CH, N, O or C(O);

[0036] X3, X4, and X5 are each independently selected from C or N;

[0037] X6 is selected from CH or N;

[0038] Y1 is selected from CH, C(O), N, NH, O, S or does not exist;

[0039] Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S;

[0040] Ring A is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, alkenylcarboxyl, alkynylcarboxyl, or dialkylamino groups;

[0041] L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12 ) m1 -、-O-、-S-、-C(O)NR 13 -、-NR13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - An aromatic heteroalkyl or heterocyclic group, wherein the aromatic heteroalkyl or heterocyclic group is optionally substituted with one or more substituents selected from oxo, alkyl, alkenyl, alkynyl, halogen, amino, hydroxyl, cyano, nitro, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl.

[0042] R 11 R 12 R 13 or R 14 Each of the following groups is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the amino, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups;

[0043] R1, R2, R3, or R4 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, and -(CH2). n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb -(CH2) n1 C(O)NR aa R bb Or -(CH2) n1 N=S(O)R aa R bbThe amino, hydroxyl, mercapto, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl groups.

[0044] Alternatively, R1 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0045] Alternatively, R1 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0046] Alternatively, R2 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0047] Alternatively, R3 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0048] Alternatively, the two R3 groups form a cycloalkyl, heterocyclic, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0049] Alternatively, the two R1 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, deuterated alkoxy, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0050] Or, R1, R 11 It forms a cycloalkyl, heterocyclic, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0051] R aa or R bb Each of the following groups is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups, wherein the amino, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, alkylacyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups;

[0052] x, y, or t are each independently 0, 1, 2, 3, or 4;

[0053] z is 0, 1, or 2;

[0054] m1 can be 0, 1, 2, or 3;

[0055] n1 or n2 can be 0, 1, 2 or 3 independently;

[0056] The conditions are:

[0057] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not...

[0058] Alternatively, when X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0059] Alternatively, when X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0060] In a preferred embodiment of the invention, at least one R4 is -(CH2). n1 O(CH2) n2 R aa R aa C 3-6 cycloalkyl, optionally further C 1-3 Alkyl substitution.

[0061] In a preferred embodiment of the invention, the compound represented by general formula (I) or (I-1) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (II-1), (II-2), or (II-3) or a pharmaceutically acceptable salt thereof:

[0062] in:

[0063] Selected from

[0064] M1 is selected from N or C;

[0065] M2, M3, or M4 are each independently selected from N or CH;

[0066] M6 or M5 are each independently selected from N, NH, CH or C(O);

[0067] L3 is selected from -O(CR) 11 R 12 ) m1 -、-(CR 11 R 12 ) m1 -、-C(O)NR 13 -、-NR 13 C(O)- or -NR 14 -;

[0068] The ring C is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents are selected from aryl, 3-14 heteroaryl, or carboxyl groups, preferably C. 3-6 cycloalkyl;

[0069] Ring D is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0070] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1- 8-cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0071] Alternatively, R6 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0072] Alternatively, R6 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0073] Alternatively, the two R6 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0074] R7 or R8 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0075] Alternatively, the two R8 atoms form a heterocyclic or heteroaryl group with the adjacent atom, wherein the heterocyclic or heteroaryl group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0076] R 11 R 12 R13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1- 8-Haloalkoxy, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents in the aryl or 3-14 heteroaryl groups are used for substitution;

[0077] R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0078] s is 0, 1, or 2;

[0079] w can be 0, 1, 2, 3, or 4;

[0080] r can be 0, 1, 2, or 3;

[0081] v is 0, 1, or 2;

[0082] m1 can be 0, 1, 2, or 3;

[0083] n3 is either 0 or 1.

[0084] In a preferred embodiment of the invention, the compound represented by general formula (II-1) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (III-1) or a pharmaceutically acceptable salt thereof, the compound represented by general formula (II-2) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (III-2) or a pharmaceutically acceptable salt thereof, and the compound represented by general formula (II-3) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (III-3) or a pharmaceutically acceptable salt thereof.

[0085] In a preferred embodiment of the invention, the compound represented by formula (III-1) or a pharmaceutically acceptable salt thereof is further represented by formula (IV-1), the compound represented by formula (III-2) or a pharmaceutically acceptable salt thereof is further represented by formula (IV-2), and the compound represented by formula (III-3) or a pharmaceutically acceptable salt thereof is further represented by formula (IV-3).

[0086] In a preferred embodiment of the invention, the compound represented by formula (IV-1) or a pharmaceutically acceptable salt thereof is further represented by formula (V-1) or (V-2) or a pharmaceutically acceptable salt thereof; the compound represented by formula (IV-2) or a pharmaceutically acceptable salt thereof is further represented by formula (V-3) or (V-4) or a pharmaceutically acceptable salt thereof; and the compound represented by formula (IV-3) or a pharmaceutically acceptable salt thereof is further represented by formula (V-5) or (V-6) or a pharmaceutically acceptable salt thereof.

[0087] In a preferred embodiment of the invention, the compound represented by general formula (I) or (I-1) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (II-4), (II-5) or (II-6) or a pharmaceutically acceptable salt thereof:

[0088] in:

[0089] Selected from

[0090] M1 is selected from N or C;

[0091] M2, M3, or M4 are each independently selected from N or CH;

[0092] M6 or M5 are each independently selected from N, NH, CH or C(O);

[0093] L3 is selected from -O(CR) 11 R 12 ) m1 -、-(CR 11 R 12 ) m1 -、-C(O)NR 13 -、-NR 13 C(O)- or -NR 14 -;

[0094] Z1 is selected from C 1-8 Alkyl, C 1-8Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Hydroxyalkyl or C 1- 8-Cyanosubstituted alkyl groups;

[0095] Ring D is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0096] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1- 8-cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0097] Alternatively, R6 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0098] Alternatively, R6 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0099] Alternatively, the two R6 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0100] R8 groups are independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1- 8-cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1- 8-alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1- 8-Haloalkoxy, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0101] Alternatively, the two R8 atoms form a heterocyclic or heteroaryl group with the adjacent atom, wherein the heterocyclic or heteroaryl group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0102] R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1- 8-Haloalkoxy, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents in the aryl or 3-14 heteroaryl groups are used for substitution;

[0103] R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0104] s is 0, 1, or 2;

[0105] w can be 0, 1, 2, 3, or 4;

[0106] v is 0, 1, or 2;

[0107] m1 can be 0, 1, 2, or 3;

[0108] n3 is either 0 or 1.

[0109] In a preferred embodiment of the invention, the compound represented by general formula (II-4) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (III-4) or a pharmaceutically acceptable salt thereof, the compound represented by general formula (II-5) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (III-5) or a pharmaceutically acceptable salt thereof, and the compound represented by general formula (II-6) or a pharmaceutically acceptable salt thereof is further represented by the compound represented by general formula (III-6) or a pharmaceutically acceptable salt thereof.

[0110] in:

[0111] Z1 is selected from C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl or C 1- 6-Cyanosubstituted alkyl group.

[0112] In a preferred embodiment of the invention, the compound represented by formula (III-4) or a pharmaceutically acceptable salt thereof is further represented by formula (IV-4), the compound represented by formula (III-5) or a pharmaceutically acceptable salt thereof is further represented by formula (IV-5), and the compound represented by formula (III-6) or a pharmaceutically acceptable salt thereof is further represented by formula (IV-6).

[0113] In a preferred embodiment of the invention, the compound represented by formula (IV-4) or a pharmaceutically acceptable salt thereof is further represented by formula (V-7) or (V-8) or a pharmaceutically acceptable salt thereof; the compound represented by formula (IV-5) or a pharmaceutically acceptable salt thereof is further represented by formula (V-9) or (V-10) or a pharmaceutically acceptable salt thereof; and the compound represented by formula (IV-6) or a pharmaceutically acceptable salt thereof is further represented by formula (V-11) or (V-12) or a pharmaceutically acceptable salt thereof.

[0114] In a preferred embodiment of the present invention, Z1 is selected from C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Hydroxyalkyl or C 1-3 Cyano-substituted alkyl groups;

[0115] In a preferred embodiment of the present invention, Z1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, or trifluoroethyl.

[0116] In a preferred embodiment of the present invention, Z1 is selected from isopropyl.

[0117] In a preferred embodiment of the present invention Selected from

[0118] In a preferred embodiment of the present invention Selected from

[0119] In a preferred embodiment of the present invention Selected from

[0120] In a preferred embodiment of the present invention Selected from

[0121] In a preferred embodiment of the present invention Selected from

[0122] In a preferred embodiment of the present invention Selected from

[0123] In a preferred embodiment of the present invention Selected from

[0124] In a preferred embodiment of the present invention Selected from

[0125] In a preferred embodiment of the present invention Selected from

[0126] In a preferred embodiment of the present invention, L3 is selected from -O-, -OCH2-, -CH2-, -NHC(O)-, -C(O)NH-, -NH- or -N(CH3)-.

[0127] In a preferred embodiment of the present invention, L3 is selected from -O- or -OCH2-; cyclic C is selected from C 3-6 Cycloalkyl.

[0128] In a preferred embodiment of the invention, for compounds of general formulas (V-1), (V-2), (V-3), (V-4), (V-5), (V-6), (V-7), (V-8), (V-9), (V-10), (V-11), or (V-12), or their pharmaceutically acceptable salts:

[0129] Selected from

[0130] Selected from

[0131] Selected from

[0132] R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-10 heteroaryl groups containing 1-3 N, O or S atoms, carboxyl, -OR aa -NR aa R bb -NR aa C(O)R bb -C(O)NR aa R bb Or -N = S(O)R aa R bbThe amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0133] R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, and a carboxyl group, wherein the amino, hydroxyl, and C groups are present. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group is substituted with one or more substituents selected from 1-3 5-10 heteroaryl or carboxyl groups chosen from N, O or S atoms;

[0134] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3- 10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1- 3-alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0135] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino, hydroxyl, mercapto, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-3Alkyl, C 1- 3-Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0136] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino, hydroxyl, mercapto, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-3 Alkyl, C 1- 3-Deuterated alkyl, C 2-4 alkenyl, C2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0137] Alternatively, the two R8 atoms form a 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms, or a 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms. The 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms, or the 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms, may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo group, or C. 1-3 One or more substituents in the alkyl group are substituted;

[0138] R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3- 10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1- 3-alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0139] z is 0, 1, or 2;

[0140] s is 0, 1, or 2;

[0141] w can be 0, 1, 2, 3, or 4;

[0142] r can be 0, 1, 2, or 3;

[0143] v can be 0, 1, or 2.

[0144] In a preferred embodiment of the present invention, for general formulas (V-1), (V-2), (V-3), (V-4), (V-5), (V-6), (V-7), (V-8), (V-9), (V-10), (V-11), or (V-12):

[0145] Selected from

[0146] Selected from

[0147] Selected from

[0148] R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2. The groups mentioned are amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2, Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0149] R6 is selected from fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0150] R7 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and acetyl.

[0151] R8 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -CD3, -OCD3, -SCH3, -OCF3. The groups mentioned are amino, methylamino, dimethylamino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3. Optionally substituted by one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0152] Alternatively, two R8 atoms form with adjacent atoms. Optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl;

[0153] R9 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -CD3 or -OCF3;

[0154] z is 0, 1, or 2;

[0155] s is 0, 1, or 2;

[0156] w can be 0, 1, 2, 3, or 4;

[0157] r can be 0, 1, 2, or 3;

[0158] v can be 0, 1, or 2.

[0159] In a preferred embodiment of the invention, for compounds of general formula (I-1) or their pharmaceutically acceptable salts:

[0160] X1 or X2 is independently selected from CH, N or O;

[0161] X3, X4, and X5 are each independently selected from C or N;

[0162] X6, Y1, Y2, Y3, Y4 or Y5 are each independently selected from CH or N;

[0163] Ring A is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, alkenylcarboxyl, or alkynylcarboxyl groups.

[0164] L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12 ) m1- -O-, -S-, -C(O)NR13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - An aromatic heteroalkyl or heterocyclic group, wherein the aromatic heteroalkyl or heterocyclic group is optionally substituted with one or more substituents selected from oxo, alkyl, alkenyl, alkynyl, halogen, amino, hydroxyl, cyano, nitro, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl.

[0165] R 11 R 12 R 13 Or R 14 Each of the following groups is independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl;

[0166] R1, R2, R3, or R4 are each independently selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl, wherein the amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl is optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl.

[0167] Alternatively, R1 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups.

[0168] Alternatively, R1 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups.

[0169] Alternatively, R2 and R3 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups.

[0170] Alternatively, R2 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups.

[0171] Alternatively, R3 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups.

[0172] Alternatively, when z is 2, the two R3s form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents from the group consisting of hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano-substituted alkyl groups.

[0173] x, y, z, or t are each independently 0, 1, 2, or 3;

[0174] m1 can be 0, 1, 2, or 3;

[0175] The conditions are:

[0176] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not [a specific value].

[0177] When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0178] When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0179] In a preferred embodiment of the invention, for compounds of general formula (I-1) or their pharmaceutically acceptable salts:

[0180] X1 or X2 is independently selected from CH, N or O;

[0181] X3, X4, and X5 are each independently selected from C or N;

[0182] X6, Y1, Y2, Y3, Y4 or Y5 are each independently selected from CH or N;

[0183] Ring A is selected from C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-12 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-12 heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, or C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 The aryl group or one or more substituents of a 5-12 membered heteroaryl group containing 1-3 N, O or S atoms are used for substitution.

[0184] L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12) m1- -O-, -S-, -C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-8 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-8 membered heterocyclic heterocyclic group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted;

[0185] R 11 R 12 R 13 or R 14 Each is independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2- 3-Alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3 alkyl groups, including amino, hydroxyl, cyano, nitro, and C groups. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1- 3-alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl groups, optionally replaced by hydroxyl, halogen, cyano, amino, or C groups. 1-3 Alkyl, C 1-3 Haloalkyl, C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 It is substituted by one or more substituents, including aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms;

[0186] R1, R2, or R4 are each independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 2- 6-olefin, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1- 6-alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted to halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution;

[0187] Alternatively, R1 and R2 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0188] Alternatively, R1 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0189] Alternatively, R2 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0190] R3 is selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6- 12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution;

[0191] Alternatively, R2 and R3 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0192] Alternatively, R3 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-12Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0193] Alternatively, when z is 2, the two R3 atoms form a C atom with the adjacent atom. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1- 6-Hydroalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0194] x, y, z, or t are each independently 0, 1, 2, or 3;

[0195] m1 can be 0, 1, 2, or 3;

[0196] The conditions are:

[0197] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not [a specific value].

[0198] When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0199] When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0200] In a preferred embodiment of the invention, for compounds of general formula (I-1) or their pharmaceutically acceptable salts:

[0201] X1 or X2 is independently selected from CH, N or O;

[0202] X3, X4, and X5 are each independently selected from C or N;

[0203] X6, Y1, Y2, Y3, Y4 or Y5 are each independently selected from CH or N;

[0204] Ring A is selected from C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-12 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-8 membered mono-heteroaryl containing 1-5 N, O or S atoms, or 8-12 membered fused heteroaryl containing 1-4 N, O or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 The aryl group, a 3-8 membered monoheterocyclic group containing 1-3 N, O or S atoms, or a 4-10 membered fused heterocyclic group containing 1-3 N, O or S atoms are substituted with one or more substituents.

[0205] L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12 ) m1- -O-, -S-, -C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-6 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-6 membered heterocyclic heteromethyl group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic heteromethyl group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2- 3-Alkenyl, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted;

[0206] R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl, wherein the amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl, optionally replaced by hydroxyl, fluorine, chlorine, bromine, cyano, amino, C 1-3 Alkyl, C 1-3One or more substituents in the haloalkyl group are substituted;

[0207] R1, R2, or R4 are each independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0208] Alternatively, R1 and R2 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted;

[0209] Alternatively, R1 and R4 form C with the adjacent atoms. 3-5 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-15 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted;

[0210] Alternatively, R2 and R4 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1- One or more substituents in the 3 alkyl group are substituted;

[0211] R3 is selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1- 3-alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0212] Alternatively, R2 and R3 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1- One or more substituents in the 3 alkyl group are substituted;

[0213] Alternatively, R3 and R4 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1- One or more substituents in the 3 alkyl group are substituted;

[0214] Alternatively, when z is 2, the two R3 atoms form a C atom with the adjacent atom. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0215] x, y, z, or t are each independently 0, 1, 2, or 3;

[0216] m1 can be 0, 1, 2, or 3;

[0217] The conditions are:

[0218] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not [a specific value].

[0219] When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0220] When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0221] In a preferred embodiment of the invention, for compounds of general formula (I-1) or their pharmaceutically acceptable salts:

[0222] X1 or X2 is independently selected from CH, N or O;

[0223] X3, X4, and X5 are each independently selected from C or N;

[0224] X6, Y1, Y2, Y3, Y4 or Y5 are each independently selected from CH or N;

[0225] Ring A is selected from C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-10 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-6 membered mono-heteroaryl containing 1-3 N, O or S atoms, or 8-10 membered fused-heteroaryl containing 1-5 N, O or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 The aryl group, a 3-6 membered monoheterocyclic group containing 1-3 N, O or S atoms, or a 6-10 membered fused heterocyclic group containing 1-3 N, O or S atoms are substituted with one or more substituents.

[0226] L1 or L2 are each independently selected from the bond, -C(O)-, -CH 2- -CHCH 3- , -O-, -S-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, It may be optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl or carboxyl;

[0227] R1, R2, or R4 are each independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, etc. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional components include hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, and C. 1-3 Alkyl, C 1-3 The alkyl halogroup is substituted by one or more substituents;

[0228] Alternatively, R1 and R2 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0229] Alternatively, R1 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0230] Alternatively, R2 and R4 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0231] R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional components include hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, and C. 1-3 Alkyl, C 1-3 The alkyl halogroup is substituted by one or more substituents;

[0232] Alternatively, R2 and R3 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0233] Alternatively, R3 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0234] Alternatively, when z is 2, the two R3 atoms form with the adjacent atoms. Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0235] x, y, z, or t are each independently 0, 1, 2, or 3;

[0236] m1 can be 0, 1, 2, or 3;

[0237] The conditions are:

[0238] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not...

[0239] When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0240] When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0241] In a preferred embodiment of the invention, for compounds of general formula (I-1) or their pharmaceutically acceptable salts:

[0242] X1 or X2 is independently selected from CH, N or O;

[0243] X3, X4, and X5 are each independently selected from C or N;

[0244] X6, Y1, Y2, Y3, Y4 or Y5 are each independently selected from CH or N;

[0245] Cycloyl A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, It may be optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl or carboxyl;

[0246] L1 or L2 are each independently selected from the bond, -C(O)-, -CH 2- -CHCH 3- , -O-, -S-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, It may be optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl or carboxyl;

[0247] R1, R2, or R4 are each independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, etc. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional components include hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, and C. 1-3 Alkyl, C 1-3 The alkyl halogroup is substituted by one or more substituents;

[0248] Alternatively, R1 and R2 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0249] Alternatively, R1 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0250] Alternatively, R2 and R4 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0251] R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional components include hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, and C. 1-3 Alkyl, C 1-3 The alkyl halogroup is substituted by one or more substituents;

[0252] Alternatively, R2 and R3 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3One or more substituents in the alkyl group are substituted;

[0253] Alternatively, R3 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0254] Alternatively, when z is 2, two R3 atoms form with adjacent atoms. Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0255] x, y, z, or t are each independently 0, 1, 2, or 3;

[0256] m1 can be 0, 1, 2, or 3;

[0257] The conditions are:

[0258] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not [a specific value].

[0259] When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0260] When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0261] In a preferred embodiment of the invention, for compounds of general formula (I-1) or their pharmaceutically acceptable salts:

[0262] X1 or X2 is independently selected from CH, N or O;

[0263] X3, X4, and X5 are each independently selected from C or N;

[0264] X6, Y1, Y2, Y3, Y4 or Y5 are each independently selected from CH or N;

[0265] Ring A is selected from Optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, or carboxyl, wherein This indicates that ring A is connected to L2;

[0266] L1 or L2 are each independently selected from the bond, -C(O)-, -CH 2- -CHCH 3- , -O-, -S-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, It may be optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl or carboxyl;

[0267] R1, R2, or R4 are each independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, etc. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional components include hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, and C. 1-3 Alkyl, C 1-3 The alkyl halogroup is substituted by one or more substituents;

[0268] Alternatively, R1 and R2 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0269] Alternatively, R1 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3One or more substituents in the alkyl group are substituted;

[0270] Alternatively, R2 and R4 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0271] R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional substitution; replaced by hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, C 1-3 Alkyl, C 1-3 One or more substituents of the haloalkyl group

[0272] Alternatively, R2 and R3 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0273] Alternatively, R3 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0274] Alternatively, when z is 2, two R3 atoms form with adjacent atoms. Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted;

[0275] x, y, z, or t are each independently 0, 1, 2, or 3;

[0276] m1 can be 0, 1, 2, or 3;

[0277] The conditions are:

[0278] When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not [a specific value].

[0279] When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0280] When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

[0281] In a preferred embodiment of the invention, for compounds of general formula (III-1), (III-2), or (III-3) or their pharmaceutically acceptable salts:

[0282] Selected from

[0283] Y1 is selected from CH, C(O), N, NH, O, S or does not exist;

[0284] Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S;

[0285] M1 is selected from N or C;

[0286] M2, M3, or M4 are each independently selected from N or CH;

[0287] M6 or M5 are each independently selected from N, NH, CH or C(O);

[0288] The ring C is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents are selected from aryl, 3-14 heteroaryl, or carboxyl groups, preferably C. 3-6 cycloalkyl;

[0289] Ring D is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0290] R2 or R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, and -(CH2). n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb Or -(CH2) n1 C(O)NR aa R bb The amino, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkoxy, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl groups.

[0291] Raa or R bb Each of the following groups is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups, wherein the amino, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, alkylacyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups;

[0292] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8-cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0293] Alternatively, R6 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0294] Alternatively, the two R6 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0295] R7 or R8 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0296] Alternatively, the two R8 atoms form a heterocyclic or heteroaryl group with the adjacent atom, wherein the heterocyclic or heteroaryl group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample;

[0297] R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution;

[0298] s is 0, 1, or 2;

[0299] w can be 0, 1, 2, 3, or 4;

[0300] r can be 0, 1, 2, or 3;

[0301] v is 0, 1, or 2;

[0302] m1 can be 0, 1, 2 or 3.

[0303] In a preferred embodiment of the invention, for compounds of general formula (III-1), (III-2), or (III-3) or their pharmaceutically acceptable salts:

[0304] Selected from

[0305] Y1 is selected from CH, C(O), N, NH, O, S or does not exist;

[0306] Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S;

[0307] M1 is selected from N or C;

[0308] M2, M3, or M4 are each independently selected from N or CH;

[0309] M6 or M5 are each independently selected from N, NH, CH or C(O);

[0310] Ring C is selected from C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 fused cycloalkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-14 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted;

[0311] Ring D is selected from C3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-14 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted;

[0312] R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 membered heteroaryl, carboxyl, -(CH2) n1 O(CH2) n2 R aa -(CH2)n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb Or -(CH2) n1 C(O)NR aa R bb The amino, hydroxyl, and C 1- 6-alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution;

[0313] R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the aforementioned amino, hydroxyl, C1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 heteroaryl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution;

[0314] R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 membered heteroaryl, carboxyl, -(CH2) n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb Or -(CH2) n1 C(O)NR aa R bbThe amino, hydroxyl, and C 1- 6-alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution;

[0315] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 1- 6-Deuterated Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution;

[0316] R7 or R8 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1-6 Alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl acyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution;

[0317] Alternatively, the two R8 atoms form a 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or a 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms. The 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or the 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0318] R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 1- 6-Deuterated Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution;

[0319] s is 0, 1, or 2;

[0320] w can be 0, 1, 2, 3, or 4;

[0321] r can be 0, 1, 2, or 3;

[0322] v is 0, 1, or 2;

[0323] m1 can be 0, 1, 2 or 3.

[0324] In a preferred embodiment of the invention, for compounds of general formula (III-1), (III-2), or (III-3) or their pharmaceutically acceptable salts:

[0325] Selected from

[0326] Y1 is selected from CH, C(O), N, NH, O, S or does not exist;

[0327] Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S;

[0328] M1 is selected from N or C;

[0329] M2, M3, or M4 are each independently selected from N or CH;

[0330] M6 or M5 are each independently selected from N, NH, CH or C(O);

[0331] Ring C is selected from C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-13 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, a 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or an 8-13 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted;

[0332] Ring D is selected from C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-13 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, a 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or an 8-13 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted;

[0333] R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-10 heteroaryl groups containing 1-3 N, O or S atoms, carboxyl, -OR aa -NR aa R bb -NR aa C(O)R bb or -C(O)NR aa R bb The amino, hydroxyl, and C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2- 4-Alynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3- 10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0334] R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, and a carboxyl group, wherein the amino, hydroxyl, and C groups are present. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group is substituted with one or more substituents selected from 1-3 5-10 heteroaryl or carboxyl groups chosen from N, O or S atoms;

[0335] R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-10 heteroaryl groups containing 1-3 N, O or S atoms, carboxyl, -OR aa -NR aa R bb -NR aa C(O)R bb or -C(O)NR aa R bb The amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1- 3-alkoxy group, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0336] R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3- 10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1- 3-alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0337] R7 or R8 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino, hydroxyl, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2- 4-Alynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3- 10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0338] Alternatively, the two R8 atoms form a 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms, or a 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms. The 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms, or the 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms, may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo group, or C. 1-3 One or more substituents in the alkyl group are substituted;

[0339] R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3- 10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1- 3-alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0340] s is 0, 1, or 2;

[0341] w can be 0, 1, 2, 3, or 4;

[0342] r can be 0, 1, 2, or 3;

[0343] v is 0, 1, or 2;

[0344] m1 can be 0, 1, 2 or 3.

[0345] In a preferred embodiment of the invention, for compounds of general formula (III-1), (III-2), or (III-3) or their pharmaceutically acceptable salts:

[0346] Selected from

[0347] Y1 is selected from CH, C(O), N, NH, O, S or does not exist;

[0348] Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S;

[0349] M1 is selected from N or C;

[0350] M2, M3, or M4 are each independently selected from N or CH;

[0351] M6 or M5 are each independently selected from N, NH, CH or C(O);

[0352] Cyclomeric carbon (C) is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0353] Cyclode D is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0354] R2 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3, -CD3. The groups mentioned are amino, methylamino, dimethylamino, hydroxy, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3, etc. It may be optionally substituted with one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0355] R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2. The groups mentioned are amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2, Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0356] R6 is selected from fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0357] R7 or R8 are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -CD3. The groups mentioned are amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, etc. Optionally substituted by one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0358] Alternatively, two R8 atoms form with adjacent atoms. It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl;

[0359] R9 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, or propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, or propoxy groups are optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl groups.

[0360] s is 0, 1, or 2;

[0361] w can be 0, 1, 2, 3, or 4;

[0362] r can be 0, 1, 2, or 3;

[0363] v is 0, 1, or 2;

[0364] m1 can be 0, 1, 2 or 3.

[0365] In a preferred embodiment of the invention, for compounds of general formula (III-1), (III-2), or (III-3) or their pharmaceutically acceptable salts:

[0366] Selected from

[0367] Y1 is selected from CH, C(O), N, NH, O, S or does not exist;

[0368] Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S;

[0369] M1 is selected from N or C;

[0370] M2, M3, or M4 are each independently selected from N or CH;

[0371] M6 or M5 are each independently selected from N, NH, CH or C(O);

[0372] Ring C is selected from It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0373] Ring D is selected from It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0374] R2 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3, -CD3. The groups mentioned are amino, methylamino, dimethylamino, hydroxy, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3, etc. It may be optionally substituted with one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0375] R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2. The groups mentioned are amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2, Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0376] R6 is selected from fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0377] R7 or R8 are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -CD3. The groups mentioned are amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, etc. Optionally substituted by one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0378] Alternatively, two R8 atoms form with adjacent atoms. It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl;

[0379] R9 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, or propoxy. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, or propoxy groups are optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl groups.

[0380] s is 0, 1, or 2;

[0381] w can be 0, 1, 2, 3, or 4;

[0382] r can be 0, 1, 2, or 3;

[0383] v is 0, 1, or 2;

[0384] m1 can be 0, 1, 2 or 3.

[0385] In a preferred embodiment of the invention, general formula (II-1) is further a compound represented by general formula (II-1A) or a pharmaceutically acceptable salt thereof, general formula (II-2) is further a compound represented by general formula (II-2A) or a pharmaceutically acceptable salt thereof, and general formula (II-3) is further a compound represented by general formula (II-3A) or a pharmaceutically acceptable salt thereof.

[0386] In some embodiments of the present invention, ring A is selected from C. 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 The aryl group or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 Aryl or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 heteroaryl, carboxyl, dicarboxyl 1-6 Alkylamino or -(CH2) n1 O(CH2) n2 R aa One or more substituents are substituted in the sample.

[0387] In a preferred embodiment of the present invention, ring A is selected from C. 3-10 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-12 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-12 heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, or C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 6-12 aryl, 5-12 membered heteroaryl containing 1-3 N, O or S atoms, carboxyl, dicarbonyl 1-3 Alkylamino or -(CH2) n1 O(CH2) n2 R aa One or more substituents are substituted in the sample.

[0388] In a preferred embodiment of the present invention, ring A is selected from C. 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-12 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-12 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-5 N, O, or S atoms, or 8-12 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 Aryl, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, carboxyl, dicarbonyl 1-3 Alkylamino or -(CH2)n1 O(CH2) n2 R aa One or more substituents are substituted in the sample.

[0389] In a further preferred embodiment of the present invention, ring A is selected from C. 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-11 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-10 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-10 membered fused-heteroaryl containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 Aryl, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, carboxyl, dicarbonyl 1-3 Alkylamino or -(CH2) n1 OR aa One or more substituents are substituted in the sample.

[0390] In a further preferred embodiment of the present invention, ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ... Optional radicals include hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, carboxyl, dimethylamino, and -CD3. One or more substituents are substituted in the sample.

[0391] In a further preferred embodiment of the present invention, ring A is selected from... Optional radicals include hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, carboxyl, dimethylamino, and -CD3. One or more substituents are substituted in which This indicates that ring A is connected to L2.

[0392] In some embodiments of the present invention, ring A is absent.

[0393] In some embodiments of the present invention, ring C is selected from C. 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 The aryl group or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 Aryl or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1-6 Alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution.

[0394] In a preferred embodiment of the present invention, ring C is selected from C. 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12Aryl or 5-14 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-14 membered heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted.

[0395] In a preferred embodiment of the present invention, ring C is selected from C. 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-14 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted.

[0396] In a preferred embodiment of the present invention, ring C is selected from C. 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-13 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, a 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or an 8-13 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted.

[0397] In a further preferred embodiment of the present invention, cyclic C is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0398] In a further preferred embodiment of the invention, ring C is selected from... It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0399] In a further preferred embodiment of the invention, ring C is selected from... It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0400] In some embodiments of the present invention, ring D is selected from C. 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 The aryl group or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 Aryl or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution.

[0401] In a preferred embodiment of the present invention, ring D is selected from C. 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-14 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-14 membered heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- One or more substituents of 3 alkyl or carboxyl groups are used for substitution.

[0402] In a preferred embodiment of the present invention, ring D is selected from C. 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-14 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted.

[0403] In a preferred embodiment of the present invention, ring D is selected from C. 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-13 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, a 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or an 8-13 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted.

[0404] In a further preferred embodiment of the present invention, ring D is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0405] In a further preferred embodiment of the invention, ring D is selected from... It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0406] In some embodiments of the present invention, L1 or L2 is independently selected from bond, -C(O)-, -(CR)-, etc. 11 R 12 ) m1 -、-O-、-S-、-C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - An aromatic heteroyl or heterocyclic group, wherein the aromatic heteroyl or heterocyclic group is optionally surrounded by an oxo group or a C-shaped group. 1-6 Alkyl, C2 1-6 alkenyl, C 2-6 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1- 6-alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution;

[0407] R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C6-12 Aryl or 5-12 heteroaryl groups, optionally surrounded by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, or C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 It is substituted by one or more substituents of aryl, 5-12 heteroaryl or carboxyl.

[0408] In a preferred embodiment of the present invention, L1 or L2 is independently selected from bond, -C(O)-, -(CR)-, etc. 11 R 12 ) m1 -、-O-、-S-、-C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-8 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-8 membered heterocyclic heterocyclic group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted;

[0409] R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl groups, including amino, hydroxyl, cyano, nitro, and C groups. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3 alkyl groups, optionally replaced by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 It is substituted by one or more substituents, including aryl, 5-8 member mono-heteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms.

[0410] In a preferred embodiment of the present invention, L1 or L2 is independently selected from bond, -C(O)-, -(CR)-, etc. 11 R 12 ) m1- -O-, -S-, -C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-6 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-6 membered heterocyclic heteromethyl group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic heteromethyl group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted;

[0411] R 11 R 12 R 13 Or R 14Each of the following groups is independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl, wherein the amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl groups are optionally substituted by one or more substituents selected from hydroxyl, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, or trifluoroethyl groups.

[0412] In a further preferred embodiment of the present invention, L1 or L2 is independently selected from bond, -C(O)-, and -CH. 2- , -CH(CH3)-, -O-, -S-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, The It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, or carboxyl.

[0413] In certain embodiments of the present invention, R1, R2, R3, R4, R5, R6, R7, R8, or R9 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1-6 Alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 membered heteroaryl, carboxyl, -(CH2) n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NRaa C(O)R bb -(CH2) n1 C(O)NR aa R bb Or -(CH2) n1 N=S(O)R aa R bb The amino, hydroxyl, thiol, and C groups mentioned above 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1- 6-alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution.

[0414] In some embodiments of the present invention, R1, R2 and the adjacent atoms form C 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C1-6 One or more substituents in an alkyl group are substituted.

[0415] In some embodiments of the present invention, R1, R4 and the adjacent atoms form C 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted;

[0416] In some embodiments of the present invention, R2, R4 and the adjacent atoms form C 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in an alkyl group are substituted.

[0417] In some embodiments of the present invention, R1, R 11 Forming C with the attached atoms 3-12 Cycloalkyl, 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14 membered heteroaryl groups containing 1-5 N, O, or S atoms, wherein the C 3-12 Cycloalkyl, 3-16-membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14-membered heteroaryl groups containing 1-5 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in an alkyl group are substituted.

[0418] In some embodiments of the invention, the two R1 atoms form C with the adjacent atoms. 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 The aryl group or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 Aryl or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in an alkyl group are substituted.

[0419] In some embodiments of the present invention, R3, R4 and the adjacent atoms form C 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in an alkyl group are substituted.

[0420] In some embodiments of the invention, two R3 atoms form C with the adjacent atoms. 3-12 Cycloalkyl, 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14 membered heteroaryl groups containing 1-5 N, O, or S atoms, wherein the C 3-12Cycloalkyl, 3-16-membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14-membered heteroaryl groups containing 1-5 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in an alkyl group are substituted.

[0421] In some embodiments of the present invention, R6, R2 and the adjacent atoms form C 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in an alkyl group are substituted.

[0422] In some embodiments of the invention, two R6 atoms form C with the adjacent atoms. 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 The aryl group or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 Aryl or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6One or more substituents in an alkyl group are substituted.

[0423] In some embodiments of the invention, the two R8 atoms and the adjacent atoms form a 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or a 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms. The 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or the 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in an alkyl group are substituted.

[0424] In some embodiments of the present invention, R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the aforementioned amino, hydroxyl, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1- 6-Hydroalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 heteroaryl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution.

[0425] In certain preferred embodiments of the present invention, R1, R2, R3, R4, R5, R6, R7, R8, or R9 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2- 4-Alynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6- 10 aryl, 5-10 heteroaryl groups containing 1-3 N, O, or S atoms, carboxyl, carboxyl, -OR aa -NR aa R bb -NR aa C(O)R bb -C(O)NR aa R bb Or -N = S(O)R aa R bb The amino, hydroxyl, thiol, and C groups mentioned above 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution.

[0426] In some preferred embodiments of the invention, R1, R2 and the adjacent atoms form C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in an alkyl group are substituted.

[0427] In some preferred embodiments of the invention, R1, R4 and the adjacent atoms form C 3-10 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in an alkyl group are substituted.

[0428] In some preferred embodiments of the invention, the two R1 atoms form C with the adjacent atoms. 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 The aryl group or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 Aryl or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 Alkyl, Halogenated C 1-3 Alkoxy, C1-3 Deuterated alkyl or C 1-3 One or more substituents in the deuterated alkoxy group are substituted.

[0429] In some preferred embodiments of the invention, R2, R4 and the adjacent atoms form C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in an alkyl group are substituted.

[0430] In some preferred embodiments of the invention, R3, R4 and the adjacent atoms form C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in an alkyl group are substituted.

[0431] In some preferred embodiments of the invention, the two R3 atoms form C with the adjacent atoms. 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered monoheteroaryl groups containing 1-3 N, O, or S atoms, wherein the C 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered mono-heteroaryl groups containing 1-3 N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 One or more substituents in an alkyl group are substituted.

[0432] In certain preferred embodiments of the present invention, R1, R 11 Forming C with the attached atoms 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered monoheteroaryl groups containing 1-3 N, O, or S atoms, wherein the C 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered mono-heteroaryl groups containing 1-3 N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 One or more substituents in an alkyl group are substituted.

[0433] In some preferred embodiments of the invention, R6, R2 and the adjacent atoms form C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in an alkyl group are substituted.

[0434] In certain preferred embodiments of the invention, the two R6 atoms form C with the adjacent atoms. 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 The aryl group or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 Aryl or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 Alkyl, Halogenated C 1-3 Alkoxy, C 1-3 Deuterated alkyl or C 1-3 One or more substituents in the deuterated alkoxy group are substituted.

[0435] In certain preferred embodiments of the invention, the two R8 atoms and the adjacent atoms form a 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms or a 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms. The 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms or the 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms is optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group, or C. 1-3 One or more substituents in an alkyl group are substituted.

[0436] In certain preferred embodiments of the present invention, R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, and a carboxyl group, wherein the amino, hydroxyl, and C groups are present. 1-3 Alkyl, C 1-3 Deuterated alkyl, C2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2- 4-Alynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3- 10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group is substituted with one or more substituents, including 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms.

[0437] In a further preferred embodiment of the invention, R aa Or R bb Each is independently selected from hydrogen, methyl, ethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0438] In a further preferred embodiment of the present invention, R1, R2, R3, R4, R5, R6, R7, R8, or R9 are each independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -N(CH3)2, -CD3, -OCD3, -SCH3, -OCF3, The groups mentioned are amino, methylamino, dimethylamino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -N(CH3)2. Optionally substituted by one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

[0439] In a further preferred embodiment of the invention, R1, R2 and the adjacent atoms form It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0440] In a further preferred embodiment of the invention, R1, R4 and the adjacent atoms form It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0441] In a further preferred embodiment of the invention, R2, R4 and the adjacent atoms form It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0442] In a further preferred embodiment of the invention, R3, R4 and the adjacent atoms form It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0443] In a further preferred embodiment of the invention, the two R3s form with the adjacent atoms It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0444] In a further preferred embodiment of the present invention, R1, R 11 Forming with adjacent atoms It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0445] In a further preferred embodiment of the invention, the two R1s form with the adjacent atoms It may optionally be substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, carboxyl, -CD3, or -OCF3.

[0446] In a further preferred embodiment of the invention, R6, R2 and the adjacent atoms form It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0447] In a further preferred embodiment of the invention, the two R6 atoms form a bonded structure with the adjacent atoms. It may optionally be substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, carboxyl, -CD3, or -OCF3.

[0448] In a further preferred embodiment of the invention, the two R8 atoms form a bonded structure with the adjacent atoms. It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

[0449] The present invention further provides a compound of general formula (M-1) or (M-2) or a pharmaceutically acceptable salt thereof:

[0450] in:

[0451] P1 is selected from hydrogen or an amino protecting group;

[0452] In general formula (M-1), X1, X2, X3, X4, X5, R2, R3, y and z are defined as in general formula (I); rings C, R7, R8, M1, M2, M4, M5, M6, v and r are defined as in general formula (III-1);

[0453] In general formula (M-2), the definitions of X1, X2, X3, X4, X5, R2, R3, y and z are as described in general formula (I); the definitions of rings C, R8, M1, M2, M4, M5, M6, v and Z1 are as described in general formula (III-4).

[0454] In a preferred embodiment of the present invention, P1 is selected from hydrogen, allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, triphenylmethyl, fluorenemethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-toluoxy.

[0455] In a preferred embodiment of the present invention, P1 is selected from hydrogen, 2,4-dimethoxybenzyl or tert-butoxycarbonyl.

[0456] The present invention further provides a method for preparing compounds of the aforementioned general formula or pharmaceutically acceptable salts thereof, comprising the following steps:

[0457] Deprotection of general formula (M-1A) yields a compound of general formula (M-1B) or a pharmaceutically acceptable salt thereof; then, general formula (M-1B) undergoes a condensation reaction with general formula (M-3) to yield a compound of general formula (III-1) or a pharmaceutically acceptable salt thereof.

[0458] in,

[0459] Pg is selected from amino protecting groups;

[0460] R is selected from halogen, hydroxyl group, or -C(O)OR A ;

[0461] R A Selected from C 1-6 alkyl;

[0462] The definitions of X1, X2, X3, X4, X5, R2, R3, y, and z are as described in general formula (I); the definitions of rings C, R6, R7, R8, M1, M2, M4, M5, M6, s, v, and r are as described in general formula (III-1).

[0463] In a preferred embodiment of the present invention, Pg is selected from propoxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, triphenylmethyl, fluorenemethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-toluoxy.

[0464] In a preferred embodiment of the present invention, Pg is selected from 2,4-dimethoxybenzyl or tert-butoxycarbonyl.

[0465] In a preferred embodiment of the present invention, R is selected from fluorine, chlorine, bromine, iodine or hydroxyl.

[0466] In a preferred embodiment of the present invention, R is selected from chlorine or hydroxyl.

[0467] The present invention further provides a method for preparing compounds of the aforementioned general formula or pharmaceutically acceptable salts thereof, comprising the following steps:

[0468] Deprotection of general formula (M-2A) yields a compound of general formula (M-2B) or a pharmaceutically acceptable salt thereof; then, general formula (M-2B) undergoes a condensation reaction with general formula (M-3) to yield a compound of general formula (III-4) or a pharmaceutically acceptable salt thereof;

[0469] in,

[0470] Pg is selected from amino protecting groups;

[0471] R is selected from halogen, hydroxyl group, or -C(O)OR A ;

[0472] R A Selected from C 1-6 alkyl;

[0473] The definitions of X1, X2, X3, X4, X5, R2, R3, y, and z are as described in general formula (I); the definitions of R6, R8, M1, M2, M4, M5, M6, s, v, and Z1 are as described in general formula (III-4).

[0474] In a preferred embodiment of the present invention, Pg is selected from propoxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, triphenylmethyl, fluorenemethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butoxycarbonyl, benzyl or p-toluoxy.

[0475] In a preferred embodiment of the present invention, Pg is selected from 2,4-dimethoxybenzyl or tert-butoxycarbonyl.

[0476] In a preferred embodiment of the present invention, R is selected from fluorine, chlorine, bromine, iodine or hydroxyl.

[0477] In a preferred embodiment of the present invention, R is selected from chlorine or hydroxyl.

[0478] The present invention further relates to a pharmaceutical composition comprising a therapeutically effective dose of any of the shown general formula compounds, their stereoisomers or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

[0479] In some embodiments of the invention, the pharmaceutical composition, based on free base, comprises 0.1% to 95% by weight of the compound, its stereoisomers, or a pharmaceutically acceptable salt thereof, preferably 5% to 70%, for example 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%.

[0480] In some embodiments of the invention, the pharmaceutical composition is selected from tablets, capsules, liquid formulations or injections, preferably also containing a filler, optionally a disintegrant, or further containing one or more of a flow aid or lubricant.

[0481] In some embodiments of the present invention, the pharmaceutical composition is an immediate-release formulation or a sustained-release formulation.

[0482] In some embodiments of the invention, the unit dose of the pharmaceutical composition, calculated as free base, of the compound, its stereoisomer, or a pharmaceutically acceptable salt thereof is 1-1000 mg, preferably 1-500 mg, or preferably 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg.

[0483] In some embodiments of the invention, the compound, its stereoisomers, or pharmaceutically acceptable salts thereof may be administered by any convenient method, such as oral, parenteral, oral, sublingual, nasal, rectal, intrathecal, or transdermal administration, and accordingly modified pharmaceutical compositions.

[0484] In some embodiments of the invention, the compound, its stereoisomers, or pharmaceutically acceptable salts thereof may be formulated into liquid or solid dosage forms, such as syrups, suspensions, emulsions, tablets, capsules, powders, granules, or lozenges.

[0485] The present invention further relates to the use of any of the general formula compounds shown, their stereoisomers or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions thereof in the preparation of NK inhibitor-related drugs, particularly in the preparation of NK3 inhibitor-related drugs.

[0486] The present invention further relates to the use of compounds of the general formula, their stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof in the preparation of medicaments for the treatment and / or prevention of psychotic disorders, cognitive impairment, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, seizures, obesity, inflammatory diseases, vomiting, preeclampsia, airway-related diseases, reproductive disorders, sex hormone-dependent diseases or gynecological diseases.

[0487] The present invention further relates to the use of compounds of the general formula, their stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof in the preparation of remedies for the treatment and / or prevention of menopausal syndrome, polycystic ovary syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor disorders or breast cancer-related diseases, wherein the menopausal syndrome includes symptoms such as hot flashes, sweating, palpitations, dizziness and obesity.

[0488] The present invention further relates to compounds of the general formula, their stereoisomers or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in methods for preparing medicaments for treating NK3-related and related diseases.

[0489] The present invention also relates to a method for treating, preventing, and / or treating diseases related to NK3, comprising administering to a patient a therapeutically effective dose of a compound of the general formula, its stereoisomer, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0490] The present invention also provides a method for treating disease conditions using the compounds or pharmaceutical compositions of the present invention, including but not limited to conditions related to NK3.

[0491] The present invention also relates to a method for treating NK3-related diseases in mammals, comprising administering to the mammal a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate, or derivative thereof.

[0492] Detailed description of the invention

[0493] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0494] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-Dimethylpentyl, 2,2-Dimethylpentyl, 3,3-Dimethylpentyl, 2-Ethylpentyl, 3-Ethylpentyl, n-Octyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,2-Dimethylhexyl, 3,3-Dimethylhexyl, 4,4-Dimethylhexyl, 2-Ethylhexyl, 3-Ethylhexyl, 4-Ethylhexyl, 2-Methyl-2-Ethylpentyl, 2-Methyl-3-Ethylpentyl, n-Nonyl, 2-Methyl-2-Ethylhexyl, 2-Methyl-3-Ethylhexyl, 2,2-Diethylpentyl, n-Decyl, 3,3-Diethylhexyl, 2,2-Diethylhexyl, and their various branched isomers, etc. More preferably, lower alkyl groups containing 1 to 6 carbon atoms are used. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc. Alkyl groups can be substituted or unsubstituted. When substituted, the substituents can be substituted at any usable connection point. The substituents are preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carboxylic acid ester groups. The present invention preferably uses methyl, ethyl, isopropyl, tert-butyl, haloalkyl, alkoxy-substituted alkyl, and hydroxy-substituted alkyl.

[0495] The term "alkylene" refers to an alkyl group in which one hydrogen atom is further substituted, for example: "methylene" refers to -CH2-, "ethylene" refers to -(CH2)2-, "propylene" refers to -(CH2)3-, "butylene" refers to -(CH2)4-, etc. The term "alkenyl" refers to an alkyl group as defined above, consisting of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, etc. Alkenyl groups can be substituted or unsubstituted; when substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio.

[0496] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc.; polycyclic cycloalkyl groups include spirocyclic, fused-ring, and bridged-ring cycloalkyl groups, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, and cycloheptyl.

[0497] The term "spirocycloalkyl" refers to a polycyclic group consisting of 5 to 20 quintile rings sharing a single carbon atom (called a spiro atom), which may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably, it is 6 to 14 quintiles, more preferably 7 to 10 quintiles. Spirocycloalkyl groups are classified into monospirocycloalkyl, bispirocycloalkyl, or polyspirocycloalkyl groups based on the number of shared spiro atoms between the rings, with monospirocycloalkyl and bispirocycloalkyl groups being preferred. More preferably, it is a 3 / 6, 3 / 5, 4 / 4, 4 / 5, 4 / 6, 5 / 5, or 5 / 6 quintile monospirocycloalkyl group. Non-limiting examples of spirocycloalkyl groups include:

[0498] wait;

[0499] It also includes spirocyclic alkyl groups that share a spiro atom with a heterocyclic alkyl group, and non-limiting examples include:

[0500] wait.

[0501] The term "fused-ring alkyl" refers to a 5- to 20-membered polycyclic carbon group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a fully conjugated π-electron system. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered. Depending on the number of constituent rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic fused-ring alkyl, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of fused-ring alkyl include:

[0502] wait.

[0503] The term "bridged cycloalkyl" refers to a 5- to 20-membered polycyclic carbon group in which any two rings share two non-directly bonded carbon atoms. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered. Depending on the number of rings, it can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl groups include:

[0504] The cycloalkyl ring may be fused to an aryl, heteroaryl, or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl group, and non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl, etc. The cycloalkyl group may be optionally substituted or unsubstituted; when substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carboxylic acid ester group.

[0505] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which are selected from nitrogen, oxygen, or S(O). m (where m is an integer from 0 to 2) heteroatoms, but excluding the ring portions of -OO-, -OS-, or -SS-, with the remaining ring atoms being carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 8 ring atoms; most preferably, it contains 3 to 8 ring atoms; even more preferably, it contains a 3-8 membered heterocyclic group containing 1 to 3 nitrogen atoms, optionally substituted with 1 to 2 oxygen atoms, sulfur atoms, or oxo groups, including nitrogen-containing monocyclic heterocyclic groups, nitrogen-containing spirocyclic groups, or nitrogen-containing fused heterocyclic groups.

[0506] Non-limiting examples of monocyclic heterocyclic groups include pyrrolyl, imidazoyl, tetrahydrofuranyl, tetrahydrothiophenyl, dihydroimidazoyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, acrylonitrile, 1,4-diazaheptanyl, pyranyl, etc., preferably pyrrolyl, morpholinyl, piperidinyl, acrylonitrile, 1,4-diazaheptanyl, and piperazinyl. Polycyclic heterocyclic groups include spirocyclic, fused-ring, and bridged-ring heterocyclic groups; wherein the spirocyclic, fused-ring, and bridged-ring heterocyclic groups involved are optionally connected to other groups by single bonds, or further cyclically linked to other cycloalkyl, heterocyclic, aryl, and heteroaryl groups by any two or more atoms on the ring.

[0507] The term "spiroheterocyclic group" refers to a polycyclic heterocyclic group consisting of 5 to 20 member monocyclic rings sharing a single atom (called a spiro atom), wherein one or more ring atoms are selected from nitrogen, oxygen, or S(O). m The heteroatom is a carbon atom (where m is an integer from 0 to 2). It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably, it is 6 to 14 fused, more preferably 7 to 10 fused. Spirocyclic groups are classified into monospirocyclic, bispirocyclic, or multispirocyclic groups based on the number of shared spiro atoms between rings, preferably monospirocyclic and bispirocyclic groups. More preferably, they are 3 / 5, 3 / 6, 4 / 4, 4 / 5, 4 / 6, 5 / 5, or 5 / 6 monospirocyclic groups. Non-limiting examples of spirocyclic groups include: wait.

[0508] The term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with the other rings in the system. One or more rings may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. One or more ring atoms are selected from nitrogen, oxygen, or S(O). m (where m is an integer from 0 to 2) heteroatoms, with the remaining ring atoms being carbon. Preferably, it consists of 6 to 14 rings, more preferably 7 to 10 rings. Depending on the number of rings, it can be classified as a bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclic group, preferably bicyclic or tricyclic, more preferably 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include: wait.

[0509] The term "bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two non-directly bonded atoms. It may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. One or more ring atoms are selected from nitrogen, oxygen, or S(O). m(where m is an integer from 0 to 2) heteroatoms, with the remaining ring atoms being carbon. Preferably, it consists of 6 to 14 rings, more preferably 7 to 10 rings. Depending on the number of rings, it can be classified as a bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic group, preferably bicyclic, tricyclic, or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include: wait.

[0510] The heterocyclic ring may be fused to an aryl, heteroaryl, or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic group, and non-limiting examples include:

[0511] wait.

[0512] The heterocyclic group can be optionally substituted or unsubstituted. When substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carboxylic acid ester group.

[0513] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) group having a conjugated π-electron system, preferably 6- to 12-membered, such as phenyl and naphthyl. More preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclic, or cycloalkyl ring, including benzo5- to 10-membered heteroaryl, benzo3- to 8-membered cycloalkyl, and benzo3- to 8-membered heteroalkyl, preferably benzo5- to 6-membered heteroaryl, benzo3- to 6-membered cycloalkyl, and benzo3- to 6-membered heteroalkyl, wherein the heterocyclic group is a heterocyclic group containing 1-3 nitrogen, oxygen, and sulfur atoms; or may further include a ternary nitrogen-containing fused ring containing a benzene ring.

[0514] The ring connected to the parent structure is an aryl ring, and non-limiting examples include:

[0515] wait.

[0516] The aryl group can be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylic acid ester group.

[0517] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl group is preferably 5 to 12-membered, more preferably 5- or 6-membered, such as imidazolyl, furanyl, thiophene, thiazolyl, pyrazolyl, oxazolyl, pyrroleyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably triazolyl, thiophene, imidazolyl, pyrazolyl, oxazolyl, pyrimidinyl, or thiazolyl; more preferably pyrazolyl, pyrroleyl, and oxazolyl. The heteroaryl ring may be fused to an aryl, heterocyclic, or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include:

[0518] wait.

[0519] The heteroaryl group can be optionally substituted or unsubstituted. When substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylic acid ester group.

[0520] The term "alkoxy" refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexoxy. Alkoxy groups can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carboxylic acid ester group.

[0521] "Halogenated alkyl" refers to an alkyl group that has been substituted with one or more halogens, wherein the alkyl group is as defined above.

[0522] "Haloalkoxy" refers to an alkoxy group that has been substituted by one or more halogens, wherein the alkoxy group is as defined above.

[0523] "Hydroxyalkyl" refers to an alkyl group that has been replaced by a hydroxyl group, where the alkyl group is as defined above.

[0524] "Alkenyl" refers to an alkenyl group, also known as an olefinic group, which is a straight-chain or branched unsaturated aliphatic hydrocarbon group containing at least one carbon-carbon double bond, and the carbon-carbon double bond can be located anywhere within the alkenyl group. Alkenyl groups have a carbon density of 2 to 20 carbon atoms. 2-20 ), 2 to 15 (C 2-15 ), 2 to 12 (C 2-12), 2 to 10 (C 2-10 ), 2 to 8 (C 2-8 ), 2 to 6 (C 2-6 ), 2 to 4 (C 2-4 ) or 2 to 3 (C 2-3 A straight-chain or branched unsaturated hydrocarbon group containing 1 carbon atom. Non-limiting examples of alkenyl groups include: The alkenyl group described therein may be further substituted with other related groups, such as: alkyl, alkenyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylic acid ester group.

[0525] "Alynyl" refers to (CH≡C-) that contains at least one carbon-carbon triple bond, which can be located anywhere within the alkynyl group, and at least one carbon-carbon double bond, which can be located anywhere within the alkenyl group. The alkynyl group has 2 to 20 carbon atoms. 2-20 ), 2 to 15 (C 2-15 ), 2 to 12 (C 2-12 ), 2 to 10 (C 2-10 ), 2 to 8 (C 2-8 ), 2 to 6 (C 2-6 ), 2 to 4 (C 2-4 ) or 2 to 3 (C 2- 3) A straight-chain or branched unsaturated hydrocarbon group containing one carbon atom. Non-limiting examples of alkynyl groups include: The alkynyl group may be further substituted with other related groups, such as alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylic acid ester group.

[0526] The term "alkenyl carbonyl" refers to -C(O)-(alkenyl), where alkenyl is defined as described above. Non-limiting examples of alkenyl carbonyl include vinyl carbonyl, propenyl carbonyl, and butenyl carbonyl. Alkenyl carbonyl can be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carboxylic acid ester.

[0527] "Hydroxy" refers to the -OH group.

[0528] "Halogen" refers to fluorine, chlorine, bromine, or iodine.

[0529] "Amino" refers to -NH2.

[0530] “Cyano” refers to -CN.

[0531] "Nitro" refers to -NO2.

[0532] "Carbonyl" refers to -C(O)-.

[0533] "Carboxyl group" refers to -C(O)OH.

[0534] "THF" refers to tetrahydrofuran.

[0535] “EtOAc” refers to ethyl acetate.

[0536] “MeOH” refers to methanol.

[0537] "DMF" refers to N,N-dimethylformamide.

[0538] "DIPEA" refers to diisopropylethylamine.

[0539] "TFA" refers to trifluoroacetic acid.

[0540] “MeCN” refers to Yi Qing.

[0541] “DMA” stands for N,N-dimethylacetamide.

[0542] “Et2O” refers to diethyl ether.

[0543] “DCE” refers to 1,2-dichloroethane.

[0544] "DIPEA" refers to N,N-diisopropylethylamine.

[0545] “NBS” refers to N-bromosuccinimide.

[0546] “NIS” refers to N-iodosuccinimide.

[0547] The different terms such as "X is selected from A, B, or C", "X is selected from A, B, and C", "X is A, B, or C", and "X is A, B, and C" all express the same meaning, that is, X can be any one or more of A, B, and C.

[0548] The compounds of this invention include all pharmaceutically acceptable isotopically labeled compounds, wherein one or more atoms of the compounds disclosed herein are replaced by atoms having the same atomic number but a different atomic mass or mass number than those commonly found. Examples of isotopes that may be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, and examples of isotopes include tritium, etc.

[0549] All hydrogen atoms described in this invention can be replaced by their isotope deuterium, and any hydrogen atom in the compounds of the embodiments of this invention can also be replaced by a deuterium atom.

[0550] "Optional" or "optionally" means that the event or environment described below may but does not have to occur, and the description includes the possibility or absence of such event or environment. For example, "optionally alkyl-substituted heterocyclic group" means that the alkyl group may but does not have to be present, and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0551] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to five, and more preferably one to three hydrogen atoms, which are independently substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).

[0552] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity.

[0553] "Pharmaceutical acceptable salt" or "medicinal salt" refers to the salts of the compounds of this invention, which are safe and effective when used in mammals and have the appropriate biological activity.

[0554] The compounds of this invention, such as those of formulas (I) to (III) or specific compounds, are intended to include one or more of the following: a free base of the compound or a pharmaceutically acceptable salt thereof, a stereoisomer, or a mixture of two or more stereoisomers. A stereoisomer is a compound that differs only in its spatial arrangement. Stereoisomers include all diastereomers and enantiomers of the compound. An enantiomer is a stereoisomer that is a mirror image of another. A diastereomer is a stereoisomer having two or more distinct chiral centers that are not mirror images of each other. Detailed Implementation

[0555] Example

[0556] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰ ohms. -6The unit (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).

[0557] MS measurements were performed using a Finnigan LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQ advantage MAX).

[0558] HPLC determinations were performed using an Agilent 1200DAD high-performance liquid chromatograph (Sunfire C18 150×4.6mm column) and a Waters 2695-2996 high-performance liquid chromatograph (Gimini C18 150×4.6mm column).

[0559] Mean inhibition rate of kinases and IC 50 The values ​​were determined using a NovoStar microplate reader (BMG GmbH, Germany).

[0560] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a diameter of 0.15 mm to 0.2 mm, and the diameter of the silica gel plates used for thin-layer chromatography separation and purification products is 0.4 mm to 0.5 mm.

[0561] Column chromatography typically uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.

[0562] The known starting materials of this invention can be synthesized using or according to methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, and Darui Chemicals.

[0563] Unless otherwise specified in the examples, the reactions can be carried out under an argon or nitrogen atmosphere.

[0564] Argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen gas balloon with a volume of approximately 1L.

[0565] A hydrogen atmosphere refers to a reaction vessel connected to a hydrogen balloon with a volume of approximately 1L.

[0566] The pressurized hydrogenation reaction was performed using a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.

[0567] The hydrogenation reaction is usually carried out under vacuum, filled with hydrogen gas, and repeated 3 times.

[0568] The microwave reaction was performed using a CEM Discover-S 908860 microwave reactor.

[0569] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.

[0570] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20℃~30℃.

[0571] The reaction process in the examples was monitored using thin-layer chromatography (TLC). The developing solvent systems used in the reactions were: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, and D: acetone. The volume ratio of the solvents was adjusted according to the polarity of the compounds.

[0572] The eluent systems for column chromatography and the developing solvent systems for thin-layer chromatography used to purify the compounds include: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, and C: dichloromethane and acetone system. The volume ratio of the solvents is adjusted according to the polarity of the compounds, and small amounts of basic or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.

[0573] Example A

[0574] (R)-(4-Fluorophenyl)(8-Methyl-3-(2-methylpyrimidin-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl ketone

[0575] first step:

[0576] 2-Methylpyrimidine-4-carboxylic acid (2 g, 14.48 mmol) was dissolved in MeOH (30 mL), and concentrated sulfuric acid (1 mL) was added. The reaction system was refluxed in an oil bath at 80 °C for 4 hours. After the reaction was complete, the mixture was cooled to room temperature, excess solvent was concentrated, and excess acid was quenched by adding saturated sodium bicarbonate solution (20 mL). The mixture was extracted with ethyl acetate (20 mL x 2), washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (PE / EtOAc = 2:1) to finally obtain methyl 2-methylpyrimidine-4-carboxylic acid (1.8 g, yield: 81.7%).

[0577] MS m / z (ESI): 153.1 [M+H].

[0578] Step Two:

[0579] 1.8 g (11.83 mmol) of methyl 2-methylpyrimidin-4-carboxylic acid ester was dissolved in 30 mL of EtOH, and 2.27 g (70.98 mmol) of hydrazine hydrate was added. The reaction mixture was stirred in an oil bath at 80 °C for 2 hours. TLC (PE / EtOAc = 3:1) showed that the starting material had almost disappeared and new spots had formed. After the reaction solution cooled to room temperature, the excess solvent was directly concentrated to obtain crude 2-methylpyrimidin-4-carboxyhydrazide (1.8 g, crude product).

[0580] MS m / z (ESI): 153.1 [M+H].

[0581] Step 3:

[0582] (3R)-4-(4-fluorobenzoyl)-3-methyl-piperazin-2-one (1 g, 4.23 mmol) was dissolved in dichloromethane (20 mL), and sodium carbonate (1.01 g, 9.52 mmol, 1.39 mL) and triethyloxonium tetrafluoroborate (965.05 mg, 5.08 mmol) were added sequentially. The reaction mixture was stirred at room temperature (20 °C) for 2 hours. After the reaction was complete, 20 mL of saturated sodium bicarbonate solution was added to quench the reaction, followed by extraction with dichloromethane (20 mL x 3), washing with saturated brine (20 mL x 2), drying with anhydrous sodium sulfate, filtration and concentration to obtain crude product, which was then purified by column chromatography (DCM:MeOH = 20:1) to obtain the target product [(5R)-6-ethoxy-5-methyl-3,5-dihydro-2H-pyrazin-4-yl]-(4-fluorophenyl)methyl ketone (750 mg, yield: 67%).

[0583] MS m / z(ESI): 265.1 [M+H].

[0584] Step 4:

[0585] [(5R)-6-ethoxy-5-methyl-3,5-dihydro-2H-pyrazin-4-yl]-(4-fluorophenyl) methyl ketone (100 mg, 378.37 μmol) and 2-methylpyrimidin-4-carbamoylhydrazine (57.57 mg, 378.37 μmol) were dissolved in MeOH (10 mL) and stirred in an oil bath at 80 °C for 16 hours. After cooling to room temperature, the excess solvent was concentrated to obtain the crude product. The crude product was purified by preparative chromatography to obtain the target product (R)-(4-fluorophenyl)(8-methyl-3-(2-methylpyrimidin-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methyl ketone (18 mg, yield: 13.5%).

[0586] MS m / z (ESI): 353.1 [M+H].

[0587] Example B

[0588] (R)-(3-(3-chloropyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0589] first step:

[0590] Under a nitrogen atmosphere, N-chlorosuccinimide (753.74 mg, 5.64 mmol) was added to a solution of methylpyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester (1 g, 5.64 mmol) in dichloromethane (20 mL), and the mixture was stirred at 25 °C for 4 hours. The reaction solution was diluted with saturated brine (20 mL), extracted with ethyl acetate (30 mL × 3), and the organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative high-performance liquid chromatography to obtain methyl-3-chloropyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester (600 mg, 2.84 mmol, yield: 50.23%).

[0591] MS m / z(ESI): 212.0 [M+H].

[0592] Step Two:

[0593] Referring to steps two and four of Example A, (R)-(3-(3-chloropyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone was obtained.

[0594] MS m / z(ESI): 412.1 [M+H].

[0595] Example C

[0596] (R)-(3-(3-(dimethylamino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0597] Step 1: Methyl 3-bromopyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester

[0598] At room temperature, methylpyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester (0.5 g, 2.82 mmol) was dissolved in acetonitrile (10 mL), and then N-bromosuccinimide (0.55 g, 3.10 mmol) was added. The mixture was stirred at room temperature for 1 hour, and the reaction was indicated by LCMS to be complete. The product was evaporated to dryness, and the crude product was separated by Flash column chromatography (dichloromethane:ethyl acetate = 90:10) to give the target compound (0.70 g, yield: 96.9%).

[0599] MS m / z(ESI): 256.0, 258.0 [M+1].

[0600] Step 2: 3-Brompyrazole[1,5-a]pyrimidine-5-carbamoylhydrazine

[0601] At room temperature, methyl 3-bromopyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester (1.4 g, 5.47 mmol) was dissolved in methanol (20 mL), followed by the addition of hydrazine hydrate (643.24 mg, 10.94 mmol, 85% purity). The mixture was stirred overnight at room temperature, and the reaction was stopped by LCMS. The solid was filtered, washed with petroleum ether, dried, and used directly in the next step (1.22 g, yield: 87.1%).

[0602] MS m / z(ESI): 256.0, 258.0 [M+1].

[0603] Step 3: (R)-3-(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)-7-(3,5-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine

[0604] Under ice bath conditions, (3R)-4-[(2,4-dimethoxyphenyl)methyl]-3-methylpiperazin-2-one (2.50 g, 9.46 mmol) was dissolved in dichloromethane (20 mL), followed by the addition of triethyloxonium tetrafluoroboric acid (5.39 g, 28.37 mmol) in portions. After the addition was complete, the mixture was stirred at room temperature for 3 hours, and the reaction was considered complete by TLC. Under ice bath conditions, the reaction mixture was slowly added dropwise to an aqueous sodium hydroxide solution (2N, 15 mL), stirred for 10 minutes, separated, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The residue was dissolved in methanol (30 mL), and then 3-bromopyrazolo[1,5-a]pyrimidine-5-carboxylhydrazine (0.60 g, 2.34 mmol) was added. The mixture was heated to 75 °C and reacted for 14 hours. After cooling to room temperature, the reaction was considered complete by LCMS. The crude product was evaporated to dryness and separated by Flash column chromatography (dichloromethane:methanol = 96:4) to obtain the target product (0.56 g, yield: 49.3%).

[0605] MS m / z (ESI): 484.1, 486.1 [M+1].

[0606] Step 4: (R)-5-(7-(3,5-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-N,N-dimethylpyrazolo[1,5-a]pyrimidine-3-amine

[0607] At room temperature, (8R)-3-(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)-7-[(3,5-dimethoxyphenyl)methyl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine (0.23 g, 0.48 mmol), dimethylamine hydrochloride (0.06 g, 0.72 mmol), sodium trimethylsilanolate (0.16 g, 1.44 mmol), and GPhosPdG6 (45.24 mg, 0.05 mmol) were dissolved in tetrahydrofuran (4 mL), purged with nitrogen, heated to 80 °C, and reacted for 14 hours. After cooling to room temperature, LC-MS indicated the formation of the target product. The solution was evaporated to dryness, and the crude product was dissolved in ethyl acetate (20 mL), then washed with saturated brine (15 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The crude product was separated by thin-layer chromatography (DCM:MeOH = 20:1) to obtain the target product (65 mg, yield: 30.3%).

[0608] MS m / z(ESI): 449.2 [M+1].

[0609] Step 5: (R)-N,N-dimethyl-5-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)pyrazolo[1,5-a]pyrimidine-3-amine

[0610] At room temperature, (R)-5-(7-(3,5-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-N,N-dimethylpyrazolo[1,5-a]pyrimidine-3-amine (25 mg, 55.74 μmol) was dissolved in dichloromethane (3 mL), followed by the addition of trifluoroacetic acid (0.3 mL). The mixture was stirred at room temperature for 1 hour, and the reaction was considered complete by LCMS. The reaction solution was quenched with water (2 mL), and stirred at room temperature for 10 minutes. A solid precipitated out. The solid was filtered and washed with water (5 mL × 3). The pH of the reaction solution was adjusted to 10-12 with sodium hydroxide aqueous solution (2N), followed by extraction with dichloromethane (15 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The crude product was used directly in the next step (16 mg, yield: 96.2%).

[0611] MS m / z(ESI): 299.2 [M+1].

[0612] Step 6: (R)-(3-(3-(dimethylamino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone

[0613] At room temperature, (R)-N,N-dimethyl-5-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)pyrazolo[1,5-a]pyrimidine-3-amine (16 mg, 53.63 μmol) was dissolved in dichloromethane (3 mL), followed by the sequential addition of triethylamine (21.71 mg, 214.52 μmol, 29.92 μL) and 4-fluorobenzoyl chloride (11.05 mg, 69.72 μmol). The mixture was stirred at room temperature for 2 hours, and the reaction was considered complete according to LCMS. The reaction solution was diluted with dichloromethane (20 mL), then washed sequentially with saturated sodium bicarbonate solution (15 mL × 2) and saturated brine (15 mL × 1). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The crude product was then separated by reversed-phase preparative chromatography and lyophilized to obtain the target product (6.7 mg, yield: 29.7%).

[0614] MS m / z(ESI): 421.2 [M+1]. 1 H NMR(400M, CDCl3)δ8.57(br,1H),7.62-7.99(m,2H),7.48-7.52(m,2H),7.18(t,J=8.4Hz 2H),5.51-5.87(br,1H),4.95-5.20(br,1H),4.52-4.79(br,1H),4.39-4.46(m,1H),3.50-3.55(m,1H),3.08(S,6H),1.76(d,J=6.8Hz,3H).

[0615] Example D

[0616] (R)-1-(3-(2-chloropyrimidin-4-yl)-7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)pyrrolidine-2-one

[0617] first step:

[0618] Chloroacetaldehyde (12.95 g, 164.94 mmol) and 3-methylpyrazine-2-amine (12.00 g, 109.96 mmol) were dissolved in 50 mL of acetonitrile, and NaHCO3 (18.48 g, 219.95 mmol) was added. The mixture was stirred at 80 °C for 12 hours. Water was added to the reaction solution, and the mixture was extracted with EtOAc. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (PE / EtOAc = 4:1) to give 8-methylimidazo[1,2-a]pyrazine (12.5 g, yield: 85.37%).

[0619] MS m / z (ESI): 134.1 [M+H].

[0620] Step Two:

[0621] PtO2 (1.07 g, 4.69 mmol) was added to a MeOH (100 mL) solution of 12.5 g (93.88 mmol) of 8-methylimidazo[1,2-a]pyrazine. The mixture was stirred at 40 °C in H2 for 16 hours. The reaction mixture was filtered and concentrated to give (R)-8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (12 g, crude product).

[0622] MS m / z (ESI): 138.1 [M+H].

[0623] Step 3:

[0624] TEA (17.70 g, 174.95 mmol, 24.40 mL) was added to a DCM (100 mL) solution of (R)-8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (12 g, 87.48 mmol) and Boc₂O (28.64 g, 131.21 mmol). The mixture was stirred at room temperature for 4 hours. The reaction mixture was treated with water (100 mL) and ethyl acetate (100 mL). The organic layer was washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated. Column chromatography (PE / EtOAc = 1:1) was used to purify the mixture to (R)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (15 g, 63.21 mmol, 72.26% yield).

[0625] MS m / z(ESI): 238.2 [M+H].

[0626] Step 4:

[0627] At 0 °C, NIS (11.38 g, 50.57 mmol) was added to a MeCN (100 mL) solution of (R)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (10 g, 42.14 mmol). The mixture was stirred at 0 °C for 2 hours. The reaction was treated with saturated aqueous solution of Na₂SO₃ (100 mL), NaHCO₃ (100 mL), and ethyl acetate (100 mL). The organic layer was washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated. Purification by column chromatography (PE / EtOAc = 1:1) yielded (R)-3-iodo-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (10 g, 27.53 mmol, 65.34% yield).

[0628] MS m / z(ESI): 364.0 [M+H].

[0629] Step 5:

[0630] Under nitrogen atmosphere at -10°C, iPrMgCl (1M, 3.30 mL) was added to a THF (10 mL) solution of (R)-3-iodo-8-methyl-5,6-dihydroimidazolo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (1 g, 2.75 mmol), and the mixture was stirred at -10°C for 0.5 h. Tributyltin chloride (896.23 mg, 2.75 mmol) was added to the mixture, and the mixture was stirred at -10°C for 0.5 h. The reaction mixture was treated with saturated aqueous NH4Cl solution (3 mL) and ethyl acetate (3 mL). The organic layer was washed with brine (3 mL), dried over Na2SO4, filtered, and concentrated. The product was purified by column chromatography (PE / EtOAc = 1:1) to give (R)-8-methyl-3-(tributyltinyl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (620 mg, 1.18 mmol, 42.78% yield).

[0631] MS m / z (ESI): 528.2 [M+H].

[0632] Step 6:

[0633] Under nitrogen atmosphere, Pd(PPh3)4 (136.12 mg, 117.79 μmol) was added to a solution of (R)-8-methyl-3-(tributyltin)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (620 mg, 1.18 mmol), 4-bromo-2-chloropyrimidine (250.63 mg, 1.30 mmol), and K2CO3 (325.58 mg, 2.36 mmol) in 1'4-dioxane (1 mL). The mixture was stirred at 100 °C for 4 hours. The reaction was quenched with water (10 mL), and the mixture was extracted with ethyl acetate (20 mL). The organic layer was washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated. The product was purified by column chromatography (PE / EtOAc = 1:1) to obtain (R)-3-(2-chloropyrimidin-4-yl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (400 mg, 1.14 mmol, 97.07% yield).

[0634] MS m / z (ESI): 350.1 [M+H].

[0635] Step 7:

[0636] NBS (771.78 mg, 3.43 mmol) was added to a DMF (1 mL) solution of (R)-3-(2-chloropyrimidin-4-yl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (800 mg, 2.29 mmol). The mixture was stirred at 100 °C for 16 hours. The reaction was quenched with a saturated aqueous solution of Na₂SO₃ (10 mL), and extracted with ethyl acetate (30 mL). The organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated. The product was purified by column chromatography (PE / EtOAc = 1:1) to obtain (R)-2-bromo-3-(2-chloropyrimidin-4-yl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (300 mg, 699.77 μmol, 30.60% yield).

[0637] MS m / z(ESI): 428.0 [M+H].

[0638] Step 8:

[0639] To a solution of (R)-2-bromo-3-(2-chloropyrimidin-4-yl)-8-methyl-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (300 mg, 699.77 μmol) and CuI (66.64 mg, 349.89 μmol) in 1'4-dioxane (5 mL), pyrrolidone (59.55 mg, 699.7 μmol) and K2CO3 (193.42 mg, 1.40 mmol) were added, and the mixture was stirred at 100 °C for 2 hours. The reaction was quenched with water (10 mL), and the mixture was extracted with ethyl acetate (20 mL). The organic layer was washed with brine (3 mL), dried over Na2SO4, filtered, and concentrated. The product was purified by column chromatography (PE / EtOAc = 1:2) to obtain (R)-3-(2-chloropyrimidin-4-yl)-8-methyl-2-(2-oxopyrrolidone-1-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylic acid tert-butyl ester (280 mg, 646.80 μmol, 92.43% yield).

[0640] MS m / z(ESI): 433.1 [M+H].

[0641] Step 9:

[0642] TFA (73.75 mg, 646.8 μmol) was added to a DCM (5 mL) solution of (R)-3-(2-chloropyrimidin-4-yl)-8-methyl-2-(2-oxopyrrolidone-1-yl)-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-carboxylic acid tert-butyl ester (280 mg, 646.80 μmol), and the mixture was stirred at 24 °C for 2 hours. The reaction was quenched with water (10 mL), and the mixture was extracted with ethyl acetate (20 mL). The organic layer was washed with brine (3 mL), dried over Na2SO4, filtered, and concentrated to give (R)-1-(3-(2-chloropyrimidin-4-yl)-8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)pyrrolidone (210 mg, crude).

[0643] MS m / z(ESI): 333.1 [M+H].

[0644] Step 10:

[0645] DIEA (116.51 mg, 901.48 μmol, 157.02 μL) was added to a DMF (3 mL) solution of (R)-1-(3-(2-chloropyrimidin-4-yl)-8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)pyrrolidone-2-one (200 mg, 600.98 μmol), 4-fluorobenzoic acid (101.05 mg, 721.18 μmol), and HATU (226.73 mg, 600.99 μmol). The mixture was stirred at 24 °C for 12 hours. The reaction was quenched with water (10 mL), and the mixture was extracted with ethyl acetate (20 mL). The organic layer was washed with brine (3 mL), dried over Na2SO4, filtered, and concentrated. The product was separated and purified by column chromatography (PE / EtOAc = 1:2) and preparative chromatography (acidic) to obtain (R)-1-(3-(2-chloropyrimidin-4-yl)-7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-2-yl)pyrrolidone (150 mg, 329.75 μmol, 54.87% yield).

[0646] MS m / z (ESI): 455.1 [M+H].

[0647] Example 1

[0648] (R)-(3-(2-chloro-6-cyclopropoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0649] first step:

[0650] Methyl 2,6-dichloropyrimidine-4-carboxylate (1 g, 4.83 mmol) was dissolved in cyclopropanol (10 mL), and K₂CO₃ (1.34 g, 9.66 mmol) was added. The reaction system was stirred at room temperature (20 °C) for 6 hours. After the reaction was complete, the excess solvent was directly concentrated to obtain the crude product. The crude product was purified by column chromatography (Petroleum ether:Ethyl acetate = 5:1, UV = 254 nm) to obtain the target product, methyl 2-chloro-6-(cyclopropoxy)pyrimidine-4-carboxylate (350 mg, 1.53 mmol, 31.69% yield).

[0651] MS m / z(ESI): 229.0 [M+1].

[0652] Step Two:

[0653] Methyl 2-chloro-6-(cyclopropoxy)pyrimidine-4-carboxylic acid (300 mg, 1.31 mmol) was dissolved in methanol (10 mL). Under ice-water bath conditions, N₂H₄·H₂O (92.73 mg, 1.57 mmol, 85% purity) was added. The reaction mixture was allowed to reach room temperature naturally and stirred for 2 hours. TLC (Petroleum ether:Ethyl acetate = 2:1, UV = 254 nm) showed a small amount of reactant remaining and the formation of new spots. After the reaction was complete, the excess solvent was directly concentrated to obtain crude 2-chloro-6-(cyclopropoxy)pyrimidine-4-carboxyhydrazide (300 mg). The crude product was used directly in the next reaction step.

[0654] MS m / z(ESI): 229.0 [M+1].

[0655] Step 3:

[0656] (5R)-4-[(2,4-dimethoxyphenyl)methyl]-6-ethoxy-5-methyl-3,5-dihydro-2H-pyrazine (191.82 mg, 656.07 μmol) and 2-chloro-6-(cyclopropoxy)pyrimidin-4-carboxylhydrazine (100 mg, 437.38 μmol) were dissolved in methanol (10 mL) and stirred in an oil bath at 80 °C for 16 hours. After the reaction was complete, the mixture was cooled to room temperature, and the excess solvent was concentrated to obtain crude (8R)-3-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-7-[(2,4-dimethoxyphenyl)methyl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine (200 mg). The crude product was used directly in the next reaction step.

[0657] MS m / z(ESI): 457.2 [M+1].

[0658] Step 4:

[0659] Dissolve (8R)-3-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-7-[(2,4-dimethoxyphenyl)methyl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazine (200 mg, 437.71 μmol) in dichloromethane (10 mL), and add trifluoroacetic acid (1 mL). The reaction system was stirred at room temperature (20°C) for 2 hours. After the reaction was complete, 10 mL of saturated sodium bicarbonate solution was added dropwise to quench the reaction. The mixture was then extracted with dichloromethane (10 mL x 2), washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude (8R)-3-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (130 mg). The crude product was used directly in the next reaction step.

[0660] MS m / z(ESI): 307.1 [M+1].

[0661] Step 5:

[0662] 4-Fluorobenzoyl chloride (100.79 mg, 635.70 μmol, 75.11 μL) and (8R)-3-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (130 mg, 423.80 μmol) were dissolved in dichloromethane (20 mL), and triethylamine (128.65 mg, 1.27 mmol, 177.33 μL) was added. The reaction mixture was stirred at room temperature (20 °C) for 4 hours. After the reaction solution cooled to room temperature, it was diluted with water (20 mL), extracted with dichloromethane (20 mL x 2), washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC to finally obtain [(8R)-3-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-fluorophenyl) methyl ketone (27.4 mg, 63.89 μmol, 15.08% yield).

[0663] MS m / z(ESI): 429.1 [M+1]. 1H NMR (400MHz, CDCl3) δ7.68(s,1H),7.50(dd,J=8.4,5.2Hz,2H),7.18(t,J=8.4Hz,2H),5.83(s,1H),5.09–4.9 2(m,1H),4.46–4.23(m,2H),3.58-3.52(m,1H),1.78(d,J=6.8Hz,3H),1.27-1.20(m,1H),0.93–0.88(m,4H).

[0664] Example 2

[0665] (R)-(3-(6-cyclopropoxy-2-methylpyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0666] first step:

[0667] A mixture of cyclopropanol (15 mL), ethyl 6-chloro-2-methyl-4-pyrimidinecarboxylate (2 g, 9.97 mmol), and potassium carbonate (2.75 g, 19.94 mmol) was stirred at room temperature for 4 hours. Water was added to the reaction mixture, and the pH was adjusted to 10 with saturated sodium bicarbonate solution. The mixture was extracted with EtOAc, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (PE / EtOAc = 4:1) to give ethyl 6-cyclopropoxy-2-methylpyrimidine-4-carboxylate (200 mg, yield: 9.03%).

[0668] MS m / z(ESI): 223.1 [M+H].

[0669] Step Two:

[0670] A mixture of ethyl 6-cyclopropoxy-2-methylpyrimidine-4-carboxylic acid ester (200 mg, 899.93 μmol), hydrazine hydrate (159.00 mg, 2.70 mmol, 85%), and ethanol (5 mL) was stirred at room temperature for 2 hours and then concentrated to dryness under reduced pressure to give 6-cyclopropoxy-2-methylpyrimidine-4-carboxylhydrazine (190 mg, crude product).

[0671] MS m / z(ESI): 209.1 [M+H].

[0672] Step 3:

[0673] A mixture of 6-cyclopropoxy-2-methylpyrimidin-4-carboxylhydrazide (100 mg, 480.27 μmol), (R)-1-(2,4-dimethoxybenzyl)-5-ethoxy-6-methyl-1,2,3,6-tetrahydropyrazine (280.83 mg, 960.54 μmol), and ethanol (5 mL) was stirred at 80 °C for 2 hours, cooled, quenched with saturated ammonium chloride solution, and extracted with EtOAc. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (DCM / MeOH = 20:1) to give (R)-3-(6-cyclopropoxy-2-methylpyrimidin-4-yl)-7-(2,4-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (150 mg, yield: 71.55%).

[0674] MS m / z(ESI): 437.2 [M+H].

[0675] Step 4:

[0676] TFA (1 mL) was added dropwise to a DCM (5 mL) solution of (R)-3-(6-cyclopropoxy-2-methylpyrimidin-4-yl)-7-(2,4-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (150 mg, 343.64 μmol). The mixture was stirred at room temperature for 0.5 hours, evaporated to dryness, and the pH was adjusted to 10 with saturated NaHCO3 solution. The mixture was extracted three times with DCM, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The crude product was used directly in the next step to obtain (R)-3-(6-cyclopropoxy-2-methylpyrimidin-4-yl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (100 mg, crude product).

[0677] MS m / z(ESI): 287.2 [M+H].

[0678] Step 5:

[0679] Add 4-fluorobenzoyl chloride (66.45 mg, 419.09 μmol) dropwise to a DCM solution of (R)-3-(6-cyclopropoxy-2-methylpyrimidin-4-yl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (100 mg, 349.25 μmol) and triethylamine (70.68 mg, 698.49 μmol) in 3 mL, and stir at room temperature for 5 minutes. The solution was quenched with water, extracted with DCM, and the organic phase was washed with saturated brine. The solution was then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. Preparative chromatography (acidic) separation yielded (R)-(3-(6-cyclopropoxy-2-methylpyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (30 mg, yield: 20.8%).

[0680] MS m / z(ESI): 409.2 [M+H]. 1 H NMR (400MHz, CDCl3) δ7.62(s,1H),7.53–7.43(m,2H),7.17(t,J=8.5Hz,2H),5.74(s,1H),5.06(dd,J=13.8,3.7Hz, 1H),4.55(s,1H),4.41–4.19(m,2H),3.51(t,J=13.4Hz,1H),2.65(s,3H),1.75(d,J=6.9Hz,3H),0.90–0.80(m,4H).

[0681] Example 3

[0682] (R)-(3-(6-cyclopropoxy-2-ethylpyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0683] Step 1: 4-Chloro-6-cyclopropoxy-2-ethylpyrimidine

[0684] Using 4,6-dichloro-2-ethylpyrimidine and cyclopropanol as starting materials, the target product was obtained by referring to the synthesis method in the first step of Example 1.

[0685] MS m / z(ESI): 199.0 [M+H].

[0686] Step Two:

[0687] A mixture of 4-chloro-6-cyclopropoxy-2-ethylpyrimidine (3 g, 15.10 mmol), tributyl(1-ethoxyvinyl)tin (6.54 g, 18.12 mmol, 6.12 mL), tetrakis(triphenylphosphine)palladium (1.04 g, 906.12 μmol), and DMF (30 mL) was stirred at 100 °C for 6 hours under nitrogen protection. After cooling, the reaction was quenched with potassium fluoride aqueous solution, extracted with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The mixture was then separated by column chromatography (PE / EtOAc = 10:1) to give 4-cyclopropoxy-6-(1-ethoxyvinyl)-2-ethylpyrimidine (3.2 g, yield: 90.4%).

[0688] MS m / z (ESI): 235.1 [M+H].

[0689] Step 3:

[0690] Sodium periodate (2.74 g, 12.80 mmol) and potassium permanganate (202.35 mg, 1.28 mmol) were added to a solution of 4-cyclopropoxy-6-(1-ethoxyvinyl)-2-ethylpyrimidine (1 g, 4.27 mmol), 1'-4-Dioxane (10 mL), and water (10 mL). The mixture was stirred at room temperature for 2 hours, filtered, and the filtrate was extracted with EtOAc. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The filtrate was separated by column chromatography (PE / EtOAc = 4:1) to give ethyl 6-cyclopropoxy-2-ethylpyrimidine-4-carboxylic acid ester (400 mg, yield: 39.7%).

[0691] MS m / z(ESI): 237.1 [M+H].

[0692] Step 4:

[0693] The target product was obtained by using ethyl 6-cyclopropoxy-2-ethylpyrimidine-4-carboxylic acid ester as a starting material, following the synthesis method in Example 1.

[0694] 1H NMR (400MHz, CDCl3) δ7.62(s,1H),7.53–7.46(m,2H),7.17(t,J=8.5Hz,2H),5.72(s,1H),5.08(dd,J=13.8,3.7Hz,1H),4.59(s,1H),4.41 –4.19(m,2H),3.51(t,J=13.0Hz,1H),2.93(q,J=7.6Hz,2H),1.75(d,J=6.9Hz,3H),1.36(t,J=7.6Hz,3H),0.87(td,J=5.0,2.6Hz,4H).MS m / z(ESI):423.2[M+H].

[0695] Example 4

[0696] (R)-(3-(6-cyclopropoxy-2-cyclopropylpyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0697] first step:

[0698] Methyl 2-chloro-6-cyclopropoxypyrimidine-4-carboxylate (230.31 mg, 1.01 mmol), potassium cyclopropyltrifluoroborate (0.15 g, 1.01 mmol), (1,1'-bis(diphenylphosphine)ferrocene)palladium(II) dichloride (37.09 mg, 50.68 μmol), and K₂CO₃ (280.19 mg, 2.03 mmol) were dissolved in 1,4-dioxane (5 mL). The reaction system was stirred at 90 °C under nitrogen protection for 10 hours. The reaction was stopped, cooled to room temperature, and quenched with water (10 mL). The mixture was extracted with dichloromethane (10 mL × 2), and the combined organic phases were washed with saturated sodium chloride (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography using petroleum ether and ethyl acetate as eluents to give the title product, methyl 6-cyclopropoxy-2-cyclopropylpyrimidine-4-carboxylic acid (150 mg), with a yield of 63.57%.

[0699] MS m / z (ESI): 235.1 [M+H].

[0700] Step Two:

[0701] The title product (R)-(3-(6-cyclopropoxy-2-cyclopropylpyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone was obtained by the synthesis according to Example 1.

[0702] MS m / z (ESI): 435.1 [M+H]. 1 H NMR(400MHz,MeOD)δ7.65–7.55(m,2H),7.39(s,1H),7.31–7.19(m,2H),6.06–5.61(m,1H),5.01–4.93(m,1H) ,4.46–4.06(m,3H),3.77–3.60(m,1H),2.29–2.16(m,1H),1.73(d,3H),1.23–1.03(m,4H),0.94–0.72(m,4H).

[0703] Example 5

[0704] (R)-(3-(6-cyclopropoxy-2-(dimethylamino)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0705] first step:

[0706] Methyl 2-chloro-6-cyclopropoxypyrimidine-4-carboxylic acid (269.07 mg, 1.18 mmol) was dissolved in DMSO (36.13 mL), and N,N-diisopropylethylamine (456.74 mg, 3.53 mmol, 615.56 μL) and N-methylmethylamine (96.06 mg, 1.18 mmol, CL) were added. The reaction system was stirred at 80 °C for 2 hours. The reaction was stopped, cooled to room temperature, and quenched with water (10 mL). The mixture was extracted with ethyl acetate (10 mL × 2), and the combined organic phases were washed with saturated sodium chloride (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography using petroleum ether and ethyl acetate as eluents to give the title product, methyl 6-cyclopropoxy-2-(dimethylamino)pyrimidine-4-carboxylic acid (250 mg), yield: 89.53%.

[0707] MS m / z(ESI): 238.1 [M+H].

[0708] Step Two:

[0709] The title product (R)-(3-(6-cyclopropoxy-2-(dimethylamino)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone was obtained by the synthesis according to Example 1.

[0710] MS m / z(ESI): 438.2 [M+H]. 1H NMR (400MHz, DMSO) δ7.64–7.52(m,2H),7.39–7.26(m,2H),6.77(s,1H),5.88–5.47(m,1H),4.89–4.77(m,1 H),4.38–4.19(m,2H),4.16–3.83(m,1H),3.73–3.51(m,1H),3.14(s,6H),1.60(d,3H),0.88–0.66(m,4H).

[0711] Example 6

[0712] (R)-(3-(4-cyclopropoxy-6-methylpyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0713] first step:

[0714] To a 200 mL THF solution of cyclopropanol (8.03 g, 138.24 mmol) at 0 °C, NaH (7.37 g, 184.31 mmol, 60%) was added, and the mixture was stirred at 0 °C for 0.5 h. Then, a 50 mL THF solution of 2-bromo-6-methyl-4-nitropyridine (20 g, 92.16 mmol) was added dropwise, and the mixture was stirred at 0 °C for 1 h. The reaction was quenched with water, extracted with dichloromethane, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The solution was then separated by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 2-bromo-4-cyclopropoxy-6-methylpyridine (17 g, yield: 80.9%).

[0715] MS m / z(ESI): 227.9 229.9 [M+H].

[0716] Step Two:

[0717] To a solution of 2-bromo-4-cyclopropoxy-6-methylpyridine (17 g, 74.53 mmol), potassium acetate (14.63 g, 149.07 mmol), and EtOH (150 mL), Pd(dppf)Cl2 (3.27 g, 4.47 mmol) was added. After three CO substitutions, the mixture was stirred at 70 °C for 3 hours under a CO atmosphere, concentrated to dryness under reduced pressure, and extracted with EtOAc. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated to dryness under reduced pressure, and separated by column chromatography (petroleum ether / ethyl acetate = 3:1) to obtain ethyl 4-cyclopropoxy-6-methylmethylpyridine ester (11 g, yield: 66.7%).

[0718] MS m / z(ESI): 222.1 [M+H].

[0719] Step 3:

[0720] A mixture of ethyl 4-cyclopropoxy-6-methylmethylpyridinyl ester (6 g, 27.11 mmol), hydrazine hydrate (4.8 g, 81.6 mmol, 85%) and ethanol (60 mL) was stirred at room temperature for 12 hours and concentrated to dryness under reduced pressure to give 4-cyclopropoxy-6-methylmethylpyridinyl hydrazine (6 g, crude product).

[0721] MS m / z(ESI): 208.1 [M+H].

[0722] Step 4:

[0723] A mixture of 4-cyclopropoxy-6-methylmethylpyridinyl hydrazide (5 g, 24.13 mmol), (5R)-4-[(2,4-dimethoxyphenyl)methyl]-6-ethoxy-5-methyl-3,5-dihydro-2H-pyrazine (10.58 g, 36.19 mmol), and EtOH (100 mL) was stirred at 80 °C for 24 hours, concentrated to dryness under reduced pressure, and separated by column chromatography (DCM / MeOH = 10:1) to give (R)-3-(4-cyclopropoxy-6-methylpyridin-2-yl)-7-(2,4-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (7 g, yield: 66.6%).

[0724] MS m / z(ESI): 436.2 [M+H].

[0725] Step 5:

[0726] TFA (25 mL) was added dropwise to a DCM (100 mL) solution of (R)-3-(4-cyclopropoxy-6-methylpyridin-2-yl)-7-(2,4-dimethoxybenzyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (7 g, 16.07 mmol), stirred at room temperature for 0.5 hours, concentrated, cooled, and water and DCM were added. A solid precipitated out. The mixture was then filtered. The filtrate was adjusted to pH 10 with 3M NaOH under ice bath conditions, extracted three times with DCM, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The crude product was used directly in the next step to obtain (R)-3-(4-cyclopropoxy-6-methylpyridin-2-yl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (4 g, yield: 87.2%).

[0727] MS m / z(ESI): 286.2 [M+H].

[0728] Step 6:

[0729] Add 4-fluorobenzoyl chloride (2.56 g, 16.12 mmol, 1.90 mL) dropwise to a DCM solution of (R)-3-(4-cyclopropoxy-6-methylpyridin-2-yl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine (4 g, 14.02 mmol), triethylamine (1.84 g, 18.22 mmol, 2.54 mL) in 150 mL at 0 °C, and stir at room temperature for 5 minutes. The solution was quenched with water, extracted with DCM, and the organic phase was washed with saturated brine, then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The solution was purified by column chromatography (ethyl acetate) and preparative chromatography (neutral) to give [(R)-(3-(4-cyclopropoxy-6-methylpyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (3.7 g, yield: 64.8%).

[0730] MS m / z(ESI): 408.2 [M+H]. 1 H NMR(400MHz, CDCl3)δ7.84(d,1H),7.53–7.42(m,2H),7.19-7.13(m,2H),6.80(d,1H),5.71(s,1H),5.02(dd,1H ),4.57(s,1H),4.34-4.28(m,1H),3.89-3.85(m,1H),3.49(s,1H),2.51(s,3H),1.74(d,3H),0.93–0.72(m,4H).

[0731] Example 7

[0732] (R)-(3-(2-cyclopropoxy-6-methylpyridin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0733] first step:

[0734] Under a nitrogen atmosphere, potassium tert-butoxide (284.06 mg, 2.53 mmol) was added to a tetrahydrofuran (20 mL) solution of 2-fluoro-4-iodo-6-methylpyridine (500 mg, 2.11 mmol) and cyclopropanol (147.03 mg, 2.53 mmol, 160.34 μL). The reaction mixture was stirred at 0 °C for 2 hours. The reaction solution was quenched by slow addition of saturated ammonium chloride (25 mL). The reaction solution was extracted with ethyl acetate (30 mL × 3), and the organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a petroleum ether:ethyl acetate = 96:4 eluent system to obtain 2-(cyclopropoxy)-4-iodo-6-methylpyridine (160 mg, 581.64 μmol, 27.57% yield).

[0735] MS m / z(ESI): 276.0 [M+H].

[0736] Step Two:

[0737] Under a carbon monoxide atmosphere, [1,1′-bis(diphenylphosphine)ferrocene]palladium dichloride in dichloromethane (39.90 mg, 54.53 μmol) was added to a mixed solution of 2-(cyclopropoxy)-4-iodo-6-methylpyridine (150 mg, 545.29 μmol) and palladium acetate (12.24 mg, 54.53 μmol) in triethylamine (1 mL) and methanol (5 mL). After displacing the carbon monoxide gas, the reaction solution was heated to 65 °C and stirred for 2 hours. The reaction solution was cooled to room temperature, and quenched slowly with saturated brine (20 mL). The reaction solution was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using an eluent system (petroleum ether: ethyl acetate = 10:1) to give methyl 2-cyclopropoxy-6-methylisonicotinic acid ester (90 mg, 434.31 μmol, 79.65% yield).

[0738] MS m / z(ESI): 208.1 [M+H].

[0739] Step 3:

[0740] Referring to the second and fourth steps of Example A, (R)-(3-(2-cyclopropoxy-6-methylpyridin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone was obtained.

[0741] MS m / z(ESI): 408.2 [M+H].

[0742] Example 8

[0743] (R)-(3-(2-chloro-6-(cyclopropylamino)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0744] first step:

[0745] Methyl 2,6-dichloropyrimidin-4-carboxylate (5 g, 24.15 mmol) was dissolved in 1,4-dioxane (100 mL), and triethylamine (4.89 g, 48.31 mmol, 6.74 mL) and cyclopropylamine (1.38 g, 24.15 mmol) were added. The reaction mixture was stirred at room temperature (25 °C) for 6 hours. The reaction was stopped and the mixture was concentrated. The residue was purified by silica gel column chromatography using petroleum ether and ethyl acetate as eluents to give the title product, methyl 2-chloro-6-(cyclopropylamino)pyrimidin-4-carboxylate (3 g), in 54.56% yield.

[0746] MS m / z(ESI): 228.0 [M+H].

[0747] Step Two:

[0748] The title product (R)-(3-(2-chloro-6-(cyclopropylamino)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone was obtained by the synthesis according to Example 1.

[0749] MS m / z(ESI): 428.1 [M+H].

[0750] Example 9

[0751] (R)-(3-(2-chloro-6-(cyclopropylmethyl)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0752] first step:

[0753] Methyl 2,6-dichloropyrimidin-4-carboxylate (1 g, 4.83 mmol), potassium trifluoroborate (cyclopropylmethyl) (782.57 mg, 4.83 mmol), (1,1'-bis(diphenylphosphine)ferrocene)palladium(II) dichloride (176.73 mg, 241.53 μmol), and K₂CO₃ (1.34 g, 9.66 mmol) were dissolved in 1,4-dioxane (10 mL). The reaction system was stirred at 90 °C under nitrogen protection for 10 hours. The reaction was stopped, cooled to room temperature, and quenched with water (10 mL). The mixture was extracted with dichloromethane (10 mL × 2), and the combined organic phases were washed with saturated sodium chloride (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography using petroleum ether and ethyl acetate as eluents to give the title product, methyl 2-chloro-6-(cyclopropylmethyl)pyrimidine-4-carboxylic acid (150 mg), with a yield of 13.70%.

[0754] MS m / z(ESI): 227.0 [M+H].

[0755] Step Two:

[0756] The title product (R)-(3-(2-chloro-6-(cyclopropylmethyl)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone was obtained by the synthesis according to Example 1.

[0757] MS m / z(ESI): 427.1 [M+H].

[0758] Example 10

[0759] (R)-(3-(5-cyclopropoxy-6-methylpyrazin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0760] first step:

[0761] Methyl 5-chloro-6-methylpyrazine-2-carboxylate (0.5 g, 2.68 mmol) was dissolved in cyclopropanol (5 mL), and potassium carbonate (740.67 mg, 5.36 mmol) was added under nitrogen protection. The mixture was stirred at 20 °C for 12 hours. The reaction solution was quenched with saturated brine (100 mL), and the aqueous phase was extracted with ethyl acetate (30 mL × 2). The organic phases were combined, washed with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain crude product (0.49 g). The crude product was used directly in the next step. MS m / z (ESI): 209.1 [M+1]

[0762] Step Two:

[0763] The target product was synthesized according to steps two, three, five, and six of Example C.

[0764] MS m / z(ESI): 409.2 [M+1]

[0765] Example 11

[0766] (R)-1-(1-(2-chloro-6-cyclopropoxypyrimidin-4-yl)-5-(4-fluorobenzoyl)-4-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrrolidine-2-one

[0767] first step:

[0768] To a THF solution (30 mL) of cyclopropanol (1.20 g, 20.72 mmol), NaH (828.61 mg, 20.72 mmol, 60% purity) was added, and the mixture was stirred at 0 °C for 30 min. The solution was then cooled to -78 °C, and a THF solution (10 mL) of 2,4,6-trichloropyrimidine (4 g, 21.81 mmol) was added. The reaction mixture was stirred at -78 °C for 3 h, quenched with saturated brine, extracted with EtOAc, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (PE / EtOAc = 99:1) to obtain 2,4-dichloro-6-(cyclopropoxy)pyrimidine (3 g, 14.63 mmol, yield 67.09%).

[0769] MS m / z(ESI): 205.0 [M+H].

[0770] Step Two:

[0771] At room temperature, DMF-DMA (55.87 g, 468.88 mmol) was added to a DMF (300 mL) solution of tert-butyl(2R)-2-methyl-4-oxo-piperidine-1-carboxylate (50 g, 234.44 mmol). The mixture was stirred at 90 °C for 16 hours. The reaction mixture was quenched with saturated brine and extracted with ethyl acetate. The organic layer was dried over Na₂SO₄, filtered, and concentrated to give tert-butyl(2R,3E)-3-(dimethylaminomethylene)-2-methyl-4-oxo-piperidine-1-carboxylate (62.91 g, 234.43 mmol, 100.00% yield), which was used directly for the next step without further purification.

[0772] MS m / z(ESI): 269.2 [M+H].

[0773] Step 3:

[0774] A solution of tert-butyl(2R,3E)-3-(dimethylaminomethylene)-2-methyl-4-oxo-piperidine-1-carboxylate (62.91 g, 234.43 mmol) and hydrazine hydrate (56.79 g, 351.65 mmol) in EtOH (350 mL) was stirred at 50 °C for 2 h. The solution was then concentrated and purified by column chromatography (PE:EA = 1:1) and preparatively resolved to give tert-butyl(4R)-4-methyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate (16.47 g, 69.41 mmol, yield 29.61%).

[0775] MS m / z(ESI): 238.1 [M+H].

[0776] Step 4:

[0777] A DCE (30 mL) solution of tert-butyl(4R)-4-methyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate (3 g, 12.64 mmol) and NIS (4.27 g, 18.96 mmol) was stirred at 80 °C for 6 h. The reaction was quenched with an aqueous sodium bisulfite solution, extracted with ethyl acetate, and the organic layer was concentrated under vacuum. The crude product was purified by column chromatography (PE:EA = 1:1) to give tert-butyl(4R)-3-iodo-4-methyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate (2.1 g, 5.78 mmol, yield 45.74%).

[0778] MS m / z(ESI): 364.0 [M+H].

[0779] Step 5:

[0780] Add NaH (126.86 mg, 3.17 mmol, 60% purity) to a THF (10 mL) solution of tert-butyl(4R)-3-iodo-4-methyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridine-5-carboxylate (768 mg, 2.11 mmol) and stir at 0 °C for 30 minutes. Then, a THF (1 mL) solution of 2,4-dichloro-6-(cyclopropoxy)pyrimidine (433.57 mg, 2.11 mmol) was added to the above solution, and the mixture was stirred at room temperature for 18 h. The reaction solution was quenched with saturated brine, extracted with ethyl acetate, the organic layer was concentrated and purified by column chromatography (PE / EA = 1:1) to give tert-butyl(4R)-1-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-3-iodo-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate (803 mg, 1.51 mmol, yield 71.41%).

[0781] MS m / z(ESI): 532.0 [M+H].

[0782] Step 6:

[0783] Pyrrolidone-2-one (192.05 mg, 2.26 mmol), CuI (85.95 mg, 451.32 μmol), N,N,N',N'-tetramethylethylenediamine (87.41 mg, 752.20 μmol), and potassium phosphate (798.33 mg, 3.76 mmol) were added to a 1,4-dioxane solution of tert-butyl(4R)-1-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-3-iodo-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate (800 mg, 1.50 mmol). The reaction mixture was stirred at 110 °C under nitrogen protection for 18 h. The mixture was diluted with ethyl acetate and extracted by washing with saturated brine. The organic layer was dried and concentrated, and purified by column chromatography (PE / EAPE / EA = 1:1) to give tert-butyl(4R)-1-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-4-methyl-3-(2-oxopyrrolidone-1-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate (150 mg, 306.77 μmol, yield 20.39%).

[0784] MS m / z (ESI): 489.2 [M+H].

[0785] Step 7:

[0786] At room temperature, HCl / EA (5 mL) was added to a 1 mL solution of tert-butyl(4R)-1-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-4-methyl-3-(2-oxopyrrolidine-1-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate (150 mg, 306.77 μmol). The mixture was stirred for 3 h and concentrated under vacuum to give 1-[(4R)-1-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-4-methyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-3-yl]pyrrolidine-2-one (85 mg, 218.59 μmol, yield 71.26%), which was used directly for the next step without purification.

[0787] MS m / z(ESI): 389.1 [M+H].

[0788] Step 8:

[0789] At 0 °C, 4-fluorobenzoyl chloride (34.66 mg, 218.59 μmol) was added to a DCM (2 mL) solution of 1-[(4R)-1-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-4-methyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-3-yl]pyrrolidone-2-one (85 mg, 218.59 μmol) and TEA (33.18 mg, 327.89 μmol, 45.73 μL), and the mixture was stirred for 30 minutes. The reaction solution was concentrated and purified by column chromatography and high performance liquid chromatography to obtain (R)-1-(1-(2-chloro-6-cyclopropoxypyrimidin-4-yl)-5-(4-fluorobenzoyl)-4-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)pyrrolidine-2-one (20 mg, 39.14 μmol, yield 17.91%).

[0790] MS m / z (ESI): 511.2 [M+H].

[0791] Example 12

[0792] (R)-(3-(7-cyclopropoxypyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0793] Step 1: Methyl 7-cyclopropoxypyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester

[0794] Under ice bath conditions, cyclopropanol (123.51 mg, 2.13 mmol) and methyl 7-chloropyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester (0.30 g, 1.42 mmol) were dissolved in anhydrous tetrahydrofuran (3 mL), followed by the addition of potassium tert-butoxide / tetrahydrofuran solution (1.0 M, 2.13 mL). Nitrogen gas was then introduced, and the mixture was stirred under ice bath conditions for 2 hours. The reaction was considered complete by LC-MS. The solution was evaporated to dryness, and the residue was dissolved in ethyl acetate (20 mL), followed by washing with saturated brine (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The crude product was separated by Flash column chromatography to obtain the target product (0.08 g, yield: 24.2%).

[0795] MS m / z(ESI): 234.1 [M+1].

[0796] Step 2: (R)-(3-(7-cyclopropoxypyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0797] Using methyl 7-cyclopropoxypyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester as a starting material, the target compound was obtained by referring to steps two, three, five and six of Example C.

[0798] MS m / z(ESI): 434.2 [M+1].

[0799] Example 13

[0800] (R)-(3-(3-chloro-7-cyclopropoxypyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0801] Step 1: Methyl 3-chloro-7-cyclopropoxypyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester

[0802] Using methyl 7-cyclopropoxypyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester as a starting material, the target compound was obtained by referring to the first step of Example B.

[0803] MS m / z(ESI): 268.1 [M+1].

[0804] Step 2: (R)-(3-(3-chloro-7-cyclopropoxypyrazolo[1,5-a]pyrimidin-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0805] Using methyl 3-chloro-7-cyclopropoxypyrazolo[1,5-a]pyrimidine-5-carboxylic acid ester as a starting material, the target compound was obtained by referring to steps two, three, five and six of Example C.

[0806] MS m / z(ESI): 468.1 [M+1].

[0807] Example 14

[0808] (R)-7-Cyclopropoxy-5-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1-methylpyrazolo[1,5-a]pyrimidin-2(1H)-one

[0809] The title product (R)-7-cyclopropoxy-5-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1-methylpyrazolo[1,5-a]pyrimidine-2(1H)-one was synthesized according to Example 1.

[0810] MS m / z(ESI): 464.1 [M+H].

[0811] Example 15

[0812] (R)-5-Cyclopropoxy-1-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-3-methylpyridin-2(1H)-one

[0813] first step:

[0814] Under a nitrogen atmosphere, potassium tert-butoxide (572.93 mg, 5.11 mmol) was added to a tetrahydrofuran (20 mL) solution of 5-iodo-3-methyl-1H-pyridin-2-one (1 g, 4.25 mmol) and cyclopropanol (296.55 mg, 5.11 mmol, 323.39 μL). The mixture was heated to 50 °C and stirred for 2 hours. The reaction solution was cooled to room temperature and quenched slowly with saturated brine (20 mL). The reaction solution was extracted with ethyl acetate (30 mL × 3), and the organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using a dichloromethane:methanol = 10:1 eluent system to obtain 5-cyclopropoxy-3-methylpyridin-2(1H)-one (300 mg, 1.82 mmol, 42.68% yield).

[0815] MS m / z (ESI): 166.1 [M+H].

[0816] Step Two:

[0817] Under a nitrogen atmosphere, potassium tert-butoxide (52.30 mg, 466.13 μmol) was added to (R)-(4-fluorophenyl)(3-iodo-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methyl ketone (150 mg, 388.44 μmol), 5-cyclopropoxy-3-methylpyridin-2(1H)-one (64.17 mg, 388.44 μmol), and [(2-di-tert-butylphosphine- The reaction mixture was prepared by heating 2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]palladium(II)methanesulfonic acid (30.90 mg, 38.84 μmol) in a 1',4-dioxane (5 mL) solution and stirring at 120 °C for 2 hours. The reaction mixture was cooled to room temperature and quenched slowly with 20 mL of saturated brine. The reaction mixture was extracted with ethyl acetate (30 mL × 3), and the organic phases were combined, washed with 50 mL of saturated brine (2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using an eluent system (dichloromethane:methanol = 10:1) to give (R)-5-cyclopropoxy-1-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-3-methylpyridin-2(1H)-one (20 mg, 47.23 μmol, 12.16% yield).

[0818] MS m / z(ESI): 424.2 [M+H].

[0819] Example 16

[0820] (R)-(3-(6-chloro-4-cyclopropoxypyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0821] first step:

[0822] 2,6-Dichloro-4-cyclopropoxypyridine was obtained in the first step of Example 6.

[0823] MS m / z(ESI): 204.0 [M+H].

[0824] Step Two:

[0825] 2-Chloro-4-cyclopropoxy-6-(1-ethoxyvinyl)pyridine was obtained in the second step of Example 3.

[0826] MS m / z(ESI): 240.0 [M+H].

[0827] Step 3:

[0828] The ethyl 6-chloro-4-cyclopropoxymethylpyridinium ester was obtained by referring to the third step of Example 3.

[0829] MS m / z(ESI): 242.1 [M+H].

[0830] Step 4:

[0831] Referring to steps two, three, four, and five of Example 2, (R)-(3-(6-chloro-4-cyclopropoxypyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone was obtained.

[0832] MS m / z(ESI): 428.1 [M+H]. 1 H NMR (400MHz, DMSO) δ7.78(d,1H),7.66–7.51(m,2H),7.42–7.24(m,3H),5.93–5.40(m,1H),4.77–4.61(m,1H),4.3 2–4.21(m,1H),4.20–4.14(m,1H),4.12–3.73(m,1H),3.70–3.50(m,1H),1.61(d,J=6.8Hz,3H),0.97–0.70(m,4H).

[0833] Example 17

[0834] (R)-(3-(6-cyclopropoxy-2-(methylamino)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0835] (R)-(3-(2-chloro-6-cyclopropoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (100 mg, 233.18 μmol) was dissolved in DMSO (1.94 mL), and a tetrahydrofuran solution of N,N-diisopropylethylamine (90.41 mg, 699.55 μmol, 121.85 μL) and methylamine (5.07 mL, 1 M) was added. The reaction system was stirred under closed pressure at 80 °C for 2 hours. The reaction was then stopped and the solution was concentrated. Purification of the residue by silica gel column chromatography with petroleum ether and ethyl acetate as eluent yielded the title product (R)-(3-(6-cyclopropoxy-2-(methylamino)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) ketone (69 mg), yield: 69.88%.

[0836] MS m / z(ESI): 424.1 [M+H]. 1 H NMR(400MHz,MeOD)δ7.65–7.54(m,2H),7.32–7.20(m,2H),6.82(s,1H),5.97–5.61(m,1H),5.14– 4.95(m,1H),4.51–4.08(m,3H),3.77–3.57(m,1H),2.95(s,3H),1.72(d,3H),0.87–0.69(m,4H).

[0837] Example 18

[0838] (R)-(3-(6-cyclopropoxy-2-methoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0839] (R)-(3-(2-chloro-6-cyclopropoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (100 mg, 233.18 μmol) was dissolved in DMSO (1.94 mL), and 1,8-diazacyclo[5,4,0]undecene-7 (71.00 mg, 466.36 μmol) and methanol (37.36 mg, 1.17 mmol) were added. The reaction mixture was stirred under closed pressure at 80 °C for 2 hours. The reaction was then stopped and the mixture was concentrated. The residue was purified by silica gel column chromatography using petroleum ether and ethyl acetate as eluent to give the title product (R)-(3-(6-cyclopropoxy-2-methoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) ketone (15 mg), yield: 15.16%.

[0840] MS m / z (ESI): 425.1 [M+H].

[0841] Example 19

[0842] (R)-(3-(6-cyclopropoxy-2-(difluoromethoxy)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0843] first step:

[0844] The following solutions were prepared: (R)-(3-(2-chloro-6-cyclopropoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (500 mg, 1.17 mmol), KOH (327.10 mg, 5.83 mmol), 1',4-Dioxane (20 mL), and methanesulfonic acid (2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (92.57 mg, 11... A mixture of 6.59 μmol of organic matter and 10 mL of water was stirred for 12 hours under nitrogen protection at 80 °C. After cooling, the pH was adjusted to 5 with dilute hydrochloric acid. The mixture was extracted with DCM, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The filtrate was separated by column chromatography (DCM / MeOH = 10:1) to obtain (R)-(3-(6-cyclopropoxy-2-hydroxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (100 mg, yield: 20.9%).

[0845] MS m / z(ESI): 411.2 [M+H].

[0846] Step Two:

[0847] A mixture of (R)-(3-(6-cyclopropoxy-2-hydroxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (70 mg, 170.56 μmol), sodium difluorochloroacetate (52.01 mg, 341.13 μmol), potassium carbonate (49.43 mg, 358.19 μmol), and DMF (7 mL) was prepared under nitrogen protection at 65 °C. Stirred for 12 hours, quenched with saturated ammonium chloride solution, extracted with EtOAc, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by preparative chromatography (neutral) to obtain (R)-(3-(6-cyclopropoxy-2-(difluoromethoxy)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (70 mg, yield: 87.3%).

[0848] MS m / z(ESI): 461.2 [M+H]. 1 H NMR (400MHz, DMSO) δ8.00–7.55(m,3H),7.49(s,1H),7.36-7.32(m,2H),5.69(s,1H),4.73-4.70(m,1 H),4.43-4.38(m,1H),4.33-4.25(m,1H),4.04(s,1H),3.62(s,1H),1.62(d,3H),1.00–0.67(m,4H).

[0849] Example 20

[0850] (R)-(3-(6-cyclopropoxy-2-(1H-pyrazol-1-yl)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0851] Under a nitrogen atmosphere, cesium carbonate (91.17 mg, 279.82 μmol) was added to a solution of (R)-(3-(2-chloro-6-cyclopropoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) ketone (60 mg, 139.91 μmol), 1H-pyrazole (0.5 M, 363.77 μL), and the mixture was stirred at 25 °C for 3 hours. The reaction solution was quenched by slowly adding saturated ammonium chloride (20 mL). The reaction solution was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative high performance liquid chromatography (mobile phase: pure water (0.1% FA)-ACN) to give (R)-(3-(6-cyclopropoxy-2-(1H-pyrazol-1-yl)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone.

[0852] MS m / z(ESI): 461.1 [M+H]. 1 H NMR (400MHz, DMSO) δ8.78–8.67(m,1H),7.91(s,1H),7.65–7.57(m,2H),7.55(s,1H),7.39–7.27(m,2H),6.67–6.61(m,1H),5.88–5.52( m,1H),5.01–4.91(m,1H),4.56–4.48(m,1H),4.43–4.34(m,1H),4.23–3.86(m,1H),3.75–3.60(m,1H),1.63(d,3H),0.95–0.82(m,4H).

[0853] Example 21

[0854] [(8R)-3-[4-(cyclopropoxy)-6-(ethylamino)-2-pyridinyl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-fluorophenyl)methyl ketone

[0855] Under a nitrogen atmosphere, 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene) (16.23 mg, 28.05 μmol) was added to a mixed solution of (R)-(3-(6-chloro-4-cyclopropoxypyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (120 mg, 280.47 μmol), ethylamine (2 M, 701.17 μL), tris(dibenzylideneacetone)dipalladium (25.68 mg, 28.05 μmol), and cesium carbonate (228.45 mg, 701.17 μmol) in 1'4-dioxane (4 mL). After purging with nitrogen, the reaction mixture was heated to 100 °C and stirred for 8 hours. The reaction solution was cooled to room temperature and quenched slowly with saturated brine (20 mL). The reaction solution was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative high-performance liquid chromatography (mobile phase: pure water (0.1% FA)-ACN) to obtain [(8R)-3-[4-(cyclopropoxy)-6-(ethylamino)-2-pyridyl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-fluorophenyl)methyl ketone (40 mg, 91.64 μmol, 32.67% yield).

[0856] MS m / z(ESI): 437.2 [M+H]. 1 H NMR (400MHz, DMSO) δ7.64–7.51(m,2H),7.38–7.28(m,2H),6.96(d,1H),6.75–6.60(m,1H),6.20(d,1H),5.83–5.33(m,1H),4.94–4. 79(m,1H),4.33–3.78(m,3H),3.71–3.55(m,1H),3.30–3.21(m,2H),1.59(d,3H),1.15(t,3H),0.85–0.75(m,2H),0.74–0.62(m,2H).

[0857] Example 22

[0858] (R)-(3-(4-cyclopropoxy-6-(cyclopropylamino)pyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0859] The target product was obtained using cyclopropylamine as a raw material, referring to Example 21.

[0860] MS m / z(ESI): 449.2 [M+H]. 1 H NMR (400MHz, DMSO) δ7.65–7.53(m,2H),7.36–7.28(m,2H),7.06(d,1H),7.01–6.92(m,1H),6.27(d,1H),5.87–5.34(m,1H),5.04–4.86( m,1H),4.27–4.17(m,1H),4.06–3.54(m,3H),2.56–2.51(m,1H),1.60(d,3H),0.88–0.77(m,2H),0.76–0.59(m,4H),0.54–0.34(m,2H).

[0861] Example 23

[0862] (R)-(3-(6-(acetidin-1-yl)-4-cyclopropoxypyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0863] The target product was obtained with reference to Example 21.

[0864] MS m / z(ESI): 449.2 [M+H]. 1 H NMR (400MHz, DMSO) δ7.70–7.46(m,2H),7.42–7.23(m,2H),7.09(d,1H),6.01(d,1H),5.90–5.37(m,1H),4.87–4.75( m,1H),4.41–3.70(m,7H),3.68–3.50(m,1H),2.39–2.19(m,2H),1.59(d,3H),0.93–0.77(m,2H),0.76–0.55(m,2H).

[0865] Example 24

[0866] (R)-(3-(4-cyclopropoxy-5-fluoro-6-methylpyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0867] Step 1: 6-Bromo-3-fluoro-2-methylpyridin-4-ol

[0868] 6-Bromo-3-fluoro-2-methylpyridine (10 g, 52.63 mmol) was dissolved in anhydrous tetrahydrofuran (150 mL) under nitrogen protection and cooled in a dry ice-ethanol bath. Butyllithium (2.5 M, 21.05 mL) was added. The mixture was stirred at -78 °C for 0.5 h. Then, triisopropyl borate (12.87 g, 68.42 mmol) was added under dry ice-ethanol bath cooling. The mixture was stirred at -78 °C for 0.5 h. The reaction was then quenched with water (10 mL), followed by 30% hydrogen peroxide (32 mL). The reaction mixture was slowly stirred at room temperature for 0.5 h. The mixture was then extracted with saturated brine (100 mL) and ethyl acetate (50 mL × 2). The organic phases were combined, washed successively with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography (elution with dichloromethane:ethyl acetate = 100:0 to 80:20) to give the target product (6 g, yield: 55.34%).

[0869] MS m / z(ESI):206.0, 208.0[M+H].

[0870] Step 2: 6-Bromo-4-cyclopropoxy-3-fluoro-2-methylpyridine

[0871] 6-Bromo-3-fluoro-2-methylpyridin-4-ol (1 g, 4.85 mmol) and cyclopropyl bromide (5.87 g, 48.54 mmol) were dissolved in N,N-dimethylacetamide (14 mL). Under nitrogen protection, cesium carbonate (3.95 g, 12.14 mmol) and sodium iodide (363.80 mg, 2.43 mmol) were added. The mixture was stirred in a microwave at 180 °C for 3 hours. The mixture was then extracted with 100 mL of saturated brine and ethyl acetate (50 mL × 2). The organic phases were combined and washed successively with 50 mL × 4 saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography (petroleum ether:ethyl acetate = 100:0 to 85:15 elution) to give the target product (0.5 g, yield: 41.86%).

[0872] MS m / z(ESI):246.0, 248.0[M+H].

[0873] Step 3: Methyl 4-cyclopropoxy-5-fluoro-6-methylpyridinecarboxylate

[0874] 6-Bromo-4-cyclopropoxy-3-fluoro-2-methylpyridine (0.5 g, 2.03 mmol) was dissolved in methanol (15 mL) and triethylamine (3 mL). Under nitrogen protection, 1,1'-bis(diphenylphosphine)ferrocene palladium(II) chloride (74.34 mg, 101.59 μmol) and palladium acetate (19.56 mg, 101.59 μmol) were added. The mixture was stirred at 90 °C for 12 hours. The mixture was concentrated under reduced pressure. The residue was purified by rapid silica gel chromatography (eluting with petroleum ether:ethyl acetate = 100:0 to 50:50) to give the target product (0.4 g, yield: 87.41%).

[0875] MS m / z(ESI): 226.1 [M+H].

[0876] Step 4: (R)-(3-(4-cyclopropoxy-5-fluoro-6-methylpyridin-2-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone

[0877] The target product was obtained by referring to steps two through five of Example 1.

[0878] MS m / z(ESI): 426.2 [M+H]. 1 H NMR (400MHz, CDCl3) δ8.19–8.06(m,1H),7.56–7.41(m,2H),7.22–7.07(m,2H),6.00–5.48(m,1H),5.07–4.91(m,1H),4. 75–4.39(m,1H),4.39–4.18(m,1H),4.03–3.88(m,1H),3.62–3.32(m,1H),2.49(s,3H),1.74(d,3H),1.02–0.81(m,4H).

[0879] Example 25

[0880] (R)-(3-(6-cyclopropoxy-2-(1-methylacetidin-3-yl)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0881] first step:

[0882] Under a nitrogen atmosphere, morphine (76.18 mg, 874.44 μmol, 76.49 μL) was added to [(8R)-3-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-fluorophenyl)methyl ketone (250 mg, 582.96 μmol) and tert-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)acetidine-1-carboxylic acid ester (330.15 mg). The reaction mixture was prepared in a solution of N,N-dimethylformamide (8 mL) containing nickel(II) dichloride (11.60 mg, 29.15 μmol) of [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine] (1.17 mmol) and bis[2-(2,4-difluorophenyl)-5-trifluoromethylpyridine][2-2'-bi(4-tert-butylpyridine)]iridium di(hexafluorophosphate) (32.70 mg, 29.15 μmol), purged with nitrogen, and then placed under 460 nm blue light for 3 hours at 25 °C with stirring. The reaction mixture was cooled to room temperature and quenched slowly with 20 mL of saturated brine. The reaction mixture was extracted with ethyl acetate (30 mL × 3), the organic phases were combined, washed with 50 mL × 2 of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using an eluent system (dichloromethane:methanol = 96:4) to give tert-butyl(R)-3-(4-cyclopropoxy-6-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)pyrimidin-2-yl)acetidine-1-carboxylic acid ester (120 mg, 218.34 μmol, 37.45% yield).

[0883] MS m / z (ESI): 550.2 [M+H].

[0884] Step Two:

[0885] Under a nitrogen atmosphere, trifluoroacetic acid (518.67 mg, 4.55 mmol, 337.89 μL) was added to a solution of tert-butyl(R)-3-(4-cyclopropoxy-6-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)pyrimidin-2-yl)acetidine-1-carboxylic acid ester (100 mg, 181.95 μmol) in dichloromethane (2 mL), and the mixture was stirred at 25 °C for 1 hour. The reaction solution was concentrated under reduced pressure to obtain a crude product, which yielded (R)-(3-(2-(acididin-3-yl)-6-cyclopropoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (80 mg, 177.98 μmol, 97.82% yield).

[0886] MS m / z (ESI): 450.2 [M+H].

[0887] Step 3:

[0888] (R)-(3-(2-(acetidin-3-yl)-6-cyclopropoxypyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (70 mg, 155.74 μmol), formaldehyde (63.19 mg, 778.68 μmol), and acetic acid (18.70 mg, 311.47 μmol) were dissolved in methanol (2 mL), and the mixture was stirred for 1 hour. Sodium triacetylborohydride (66.01 mg, 311.47 μmol) was then added, and the mixture was stirred for another 0.5 hours. The reaction solution was cooled to room temperature and quenched slowly with saturated brine (20 mL). The reaction solution was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative high-performance liquid chromatography (mobile phase: pure water (0.1% FA)-ACN) to obtain (R)-(3-(6-cyclopropoxy-2-(1-methylacetidin-3-yl)pyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone (40 mg, 86.30 μmol, 55.41% yield).

[0889] MS m / z(ESI): 464.2 [M+H]. 1H NMR (400MHz, DMSO) δ7.64–7.55(m,2H),7.47(s,1H),7.37–7.29(m,2H),5.88–5.49(m,1H),4.93–4.80(m,1H),4.40–4.27(m,2 H),4.23–3.85(m,1H),3.81–3.72(m,1H),3.71–3.51(m,3H),3.41–3.33(m,2H),2.25(s,3H),1.62(d,3H),0.91–0.74(m,4H).

[0890] Example 26

[0891] (R)-1-(4-cyclopropoxy-6-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)pyrimidin-2-yl)cyclopropane-1-carboxynitrile

[0892] Step 1: (R)-1-(4-cyclopropoxy-6-(7-(4-fluorobenzoyl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)pyrimidin-2-yl)cyclopropane-1-carboxynitrile

[0893] At room temperature, 1-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentane-2-yl)cyclopropanenitrile (114.34 mg, 592.29 μmol), [(8R)-3-[2-chloro-6-(cyclopropoxy)pyrimidin-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-fluorophenyl)methyl ketone (127 mg, 296.14 μmol), morpholine (38.70 mg, 444.21 μmol), ( 4,4'-di-tert-butyl-2,2'-bipyridine)nickel dichloride (5.89 mg, 14.81 μmol) and (4,4'-Di-t-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-trifluoromethyl-2-pyridyl-kN)phenyl-kC]iridium(III) hexafluorophosphate (16.61 mg, 14.81 μmol) were dissolved in N,N-dimethylformamide (2 mL), purged with nitrogen, and then reacted under blue light (460 nm) at room temperature for 3 hours. The reaction was indicated by LCMS to be complete. The reaction solution was diluted with ethyl acetate (20 mL), then washed with saturated brine (10 mL × 3), the organic phase was dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. The crude product was purified by reversed-phase preparative chromatography to obtain the target compound (15.3 mg, yield: 11.2%).

[0894] MS m / z(ESI): 460.2 [M+H]. 1 H NMR (400M, CDCl3) δ7.67 (s, 1H), 7.51-7.47 (m, 2H), 7.16 (t, J = 8.0Hz 2H),6.01-5.74(br,1H),5.30-5.27(m,1H),4.61-4.40(m,2H),4.24-4.20(m,1H) ,3.61-3.55(m,1H),1.92-1.84(m,4H),1.77(d,J=6.4Hz,3H),0.86-0.83(m,4H).

[0895] Example 27

[0896] (R)-(3-(6-cyclopropoxy-2-morpholinopyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0897] Example 27 is a byproduct produced in the first step of Example 25, which was purified to obtain (R)-(3-(6-cyclopropoxy-2-morpholinopyrimidin-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methyl ketone.

[0898] MS m / z(ESI): 480.1 [M+H]. 1 H NMR (400MHz, DMSO) δ7.64–7.52(m,2H),7.38–7.27(m,2H),6.84(s,1H),5.96–5.41(m,1H) ,4.81–4.69(m,1H),4.36–3.89(m,3H),3.77–3.51(m,9H),1.60(d,3H),0.85–0.68(m,4H).

[0899] Example 28

[0900] (R)-(3-(3-cyclopropyl-8-methylimidazo[1,2-a]pyrazin-6-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl)methyl ketone

[0901] first step:

[0902] (4-Fluorophenyl)-[(8R)-8-methyl-3-(8-methylimidazo[1,2-a]pyrazin-6-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl] methyl ketone (200 mg, 510.99 μmol) was dissolved in MeCN (10 mL), and NBS (136.42 mg, 766.48 μmol) was added. The reaction mixture was stirred at room temperature (20 °C) for 2 hours. After the reaction was complete, the reaction was quenched with saturated sodium sulfite (10 mL), extracted with ethyl acetate (10 mL x 2), washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (Dichloromethane:Methanol = 20:1, UV = 254nm) to finally obtain [(8R)-3-(3-bromo-8-methyl-imidazo[1,2-a]pyrazin-6-yl)-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-fluorophenyl) methyl ketone (100 mg, 212.63 μmol, 41.61% yield).

[0903] MS m / z(ESI):470.1, 472.1[M+H].

[0904] Second time:

[0905] [(8R)-3-(3-bromo-8-methyl-imidazo[1,2-a]pyrazin-6-yl)-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-(4-fluorophenyl) methyl ketone (100 mg, 212.63 μmol) and cyclopropylboronic acid (21.92 mg, 255.16 μmol) were dissolved in a mixed solvent of H2O (5 mL) and 1',4-Dioxane (15 mL). Potassium carbonate (88.16 mg, 637.89 μmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloromethane dichloride complex (31.12 mg, 42.53 μmol) were added to the mixture. After the reaction system was purged with nitrogen several times, it was stirred in an oil bath at 80 °C for 16 hours. After the reaction solution cooled to room temperature, it was diluted with water (20 mL), extracted with dichloromethane (20 mL x 2), washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by prep-HPLC to finally obtain [(8R)-3-(3-cyclopropyl-8-methyl-imidazo[1,2-a]pyrazin-6-yl)-8-methyl-6,8-dihydro-5H-[1,2,4]triazol...

Claims

1. A compound of general formula (I) or a pharmaceutically acceptable salt thereof: in: Selected from single or double bonds; X1 or X2 is independently selected from CH, N, O or C(O); X3, X4, and X5 are each independently selected from C or N; X6 is selected from CH or N; Y1 is selected from CH, C(O), N, NH, O, S or does not exist; Y2, Y3, Y4, or Y5 are each independently selected from CH, C(O), N, NH, O, or S; Ring A is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, alkenylcarboxyl, alkynylcarboxyl, or dialkylamino groups; L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12 ) m1 -、-O-、-S-、-C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - An aromatic heteroalkyl or heterocyclic group, wherein the aromatic heteroalkyl or heterocyclic group is optionally substituted with one or more substituents selected from oxo, alkyl, alkenyl, alkynyl, halogen, amino, hydroxyl, cyano, nitro, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl. R 11 R 12 R 13 Or R 14 Each of the following groups is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the amino, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups; R1, R2, R3, or R4 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, and -(CH2). n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb -(CH2) n1 C(O)NR aa R bb Or -(CH2) n1 N=S(O)R aa R bb The amino, hydroxyl, mercapto, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted with one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, alkylthio, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups. Alternatively, R1 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, R1 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, R2 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, R3 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, the two R3 groups form a cycloalkyl, heterocyclic, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, the two R1 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, deuterated alkoxy, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Or, R1, R 11 It forms a cycloalkyl, heterocyclic, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, or heteroaryl group is optionally substituted with hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano, or -(CH2). n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; R aa Or R bb Each of the following groups is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups, wherein the amino, hydroxyl, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more substituents selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, deuterated alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, alkylacyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl groups; x, y, or t are each independently 0, 1, 2, 3, or 4; z is 0, 1, or 2; m1 can be 0, 1, 2, or 3; n1 or n2 can be 0, 1, 2 or 3 independently; The conditions are: When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not... When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not... When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, The general formula (I) is further shown as general formula (I-1): in: X1 or X2 is independently selected from CH, N or O; X3, X4, and X5 are each independently selected from C or N; X6, Y1, Y2, Y3, Y4 or Y5 are each independently selected from CH or N; Ring A is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, carboxyl, alkenylcarboxyl, or alkynylcarboxyl groups. Preferably, ring A is selected from C. 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-12 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-12 heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, or C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 The aryl group or one or more substituents of a 5-12 membered heteroaryl group containing 1-3 N, O or S atoms are used for substitution. More preferably, ring A is selected from C. 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-12 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-8 membered mono-heteroaryl containing 1-5 N, O or S atoms, or 8-12 membered fused heteroaryl containing 1-4 N, O or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 The aryl group, a 3-8 membered monoheterocyclic group containing 1-3 N, O or S atoms, or a 4-10 membered fused heterocyclic group containing 1-3 N, O or S atoms are substituted with one or more substituents. More preferably, ring A is selected from C. 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-10 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-6 membered mono-heteroaryl containing 1-3 N, O or S atoms, or 8-10 membered fused-heteroaryl containing 1-5 N, O or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 The aryl group, a 3-6 membered monoheterocyclic group containing 1-3 N, O or S atoms, or a 6-10 membered fused heterocyclic group containing 1-3 N, O or S atoms are substituted with one or more substituents. More preferably, ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ... It may be optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl or carboxyl; More preferably, ring A is selected from Optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, or carboxyl, wherein This indicates that ring A is connected to L2; L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12 ) m1- -O-, -S-, -C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - An aromatic heteroalkyl or heterocyclic group, wherein the aromatic heteroalkyl or heterocyclic group is optionally substituted with one or more substituents selected from oxo, alkyl, alkenyl, alkynyl, halogen, amino, hydroxyl, cyano, nitro, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl or carboxyl. R 11 R 12 R 13 Or R 14 Each of the following groups is independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl, optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; Preferably, L1 or L2 is independently selected from bond, -C(O)-, -(CR)-, etc. 11 R 12 ) m1- -O-, -S-, -C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-8 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-8 membered heterocyclic heterocyclic group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted; R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2- 3-olefin, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3 alkyl groups, including amino, hydroxyl, cyano, nitro, and C groups. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1- 3-alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl groups, optionally replaced by hydroxyl, halogen, cyano, amino, or C groups. 1-3 Alkyl, C 1-3 Haloalkyl, C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 It is substituted by one or more substituents, including aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms; More preferably, L1 or L2 is independently selected from bond, -C(O)-, -(CR 11 R 12 ) m1- -O-, -S-, -C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-6 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-6 membered heterocyclic heteromethyl group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic heteromethyl group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted; R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl, wherein the amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl, optionally replaced by hydroxyl, fluorine, chlorine, bromine, cyano, amino, C 1-3 Alkyl, C 1-3 One or more substituents in the haloalkyl group are substituted; More preferably, L1 or L2 is independently selected from the bond, -C(O)-, and -CH. 2- -CHCH 3- , -O-, -S-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, It may be optionally substituted with one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl or carboxyl; R1, R2, R3, or R4 are each independently selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl, wherein the amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl is optionally substituted by one or more substituents selected from halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, hydroxyalkyl, cyano-substituted alkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, or carboxyl. Alternatively, R1 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups. Alternatively, R1 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups. Alternatively, R2 and R3 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups. Alternatively, R2 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups. Alternatively, R3 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents selected from hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano alkyl groups. Alternatively, when z is 2, the two R3s form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally substituted by one or more substituents from the group consisting of hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl or cyano-substituted alkyl groups. Preferably, R1, R2, or R4 are each independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1- 6-alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted to halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution; Alternatively, R1 and R2 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, R1 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, R2 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; More preferably, R1, R2, or R4 are each independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, R1 and R2 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; Alternatively, R1 and R4 form C with the adjacent atoms. 3-5 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-15 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; Alternatively, R2 and R4 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1- One or more substituents in the 3 alkyl group are substituted; More preferably, R1, R2, or R4 are each independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, etc. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional components include hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, and C. 1-3 Alkyl, C 1-3 The alkyl halogroup is substituted by one or more substituents; Alternatively, R1 and R2 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted; Alternatively, R1 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted; Alternatively, R2 and R4 form with the adjacent atoms Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted; Preferably, R3 is selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3- 12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted to halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution; Alternatively, R2 and R3 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, R3 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, when z is 2, the two R3 atoms form a C atom with the adjacent atom. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1- 6-Hydroalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; More preferably, R3 is selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkanes , 3-10 membered heterocyclic groups containing 1-3 N, O or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1- 3-alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, R2 and R3 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1- One or more substituents in the 3 alkyl group are substituted; Alternatively, R3 and R4 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1- One or more substituents in the 3 alkyl group are substituted; Alternatively, when z is 2, the two R3 atoms form a C atom with the adjacent atom. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted; More preferably, R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, etc. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optional components include hydrogen, hydroxyl, fluorine, chlorine, bromine, cyano, amino, and C. 1-3 Alkyl, C 1-3 The alkyl halogroup is substituted by one or more substituents; Alternatively, R2 and R3 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted; Alternatively, R3 and R4 form with the adjacent atoms Hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted; Alternatively, when z is 2, the two R3 atoms form with the adjacent atoms. Optionally coated with hydrogen, halogen, amino, hydroxyl, oxo group or C 1-3 One or more substituents in the alkyl group are substituted x, y, z, or t are each independently 0, 1, 2, or 3; m1 can be 0, 1, 2, or 3; The conditions are: When X1, X2, X4, and X6 are N, X3 and X5 are C, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is -C(O)-, -CF2-, -CHCF3-, or -NHC(O)-, L2 is a bond, and R2 is selected from hydrogen, methyl, ethyl, propyl, hydroxyethyl, ... When one of the substituents is substituted, y is 0 or 1, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, ring A is not... When X1, X4, and X6 are N, X3 and X5 are C, X2, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, z is 0, and R1, R2, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not... When X2, X4, and X6 are N, X3 and X5 are C, X1, Y1, Y2, Y3, Y4, and Y5 are CH, L1 is C(O), L2 is a bond, R2 is a methyl group, y is 1, z is 1, and R1, R2, R3, and R4 do not form cycloalkyl or heterocyclic groups with the atoms they are attached to, then ring A is not...

3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that, General formula (I) or (I-1) is further shown as general formula (II-1), (II-2), or (II-3): in: Selected from M1 is selected from N or C; M2, M3, or M4 are each independently selected from N or CH; M6 or M5 are each independently selected from N, NH, CH or C(O); L3 is selected from -O(CR) 11 R 12 ) m1 -、-(CR 11 R 12 ) m1 -、-C(O)NR 13 -、-NR 13 C(O)- or -NR 14 -; preferably -O-, -OCH2-, -CH2-, -NHC(O)-, -C(O)NH-, -NH- or -N(CH3-), more preferably -O- or -OCH2-; The ring C is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents are selected from aryl, 3-14 heteroaryl, or carboxyl groups, preferably C. 3-6 cycloalkyl; Ring D is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1- 8-cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; Alternatively, R6 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, R6 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, the two R6 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; R7 or R8 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; Alternatively, the two R8 atoms form a heterocyclic or heteroaryl group with the adjacent atom, wherein the heterocyclic or heteroaryl group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1- 8-Haloalkoxy, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents in the aryl or 3-14 heteroaryl groups are used for substitution; R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; s is 0, 1, or 2; w can be 0, 1, 2, 3, or 4; r can be 0, 1, 2, or 3; v is 0, 1, or 2; m1 can be 0, 1, 2, or 3; n3 is either 0 or 1; R2, R3, R 11 R 12 R aa The definitions of Y1, Y2, Y3, Y4, Y5, y, z, n1, and n2 are as described in claim 1.

4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that, Wherein, general formula (I) or (I-1) is further shown as general formula (II-1): Selected from M1 is selected from N or C; M2, M3, M4, or M5 are each independently selected from N or CH; M6 is selected from N, CH or C(O); L3 is selected from -O-, -(CR 11 R 12 ) m1 -、-C(O)NR 13 -、-NR 13 C(O)- or -NR 14 -; preferably -O-, -CH2-, -NHC(O)- or -NH-; The ring C is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally converted by a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 Aryl, 3-14 heteroaryl, carboxyl, C 2-8 alkenyl carboxyl, C 2-8 alkynyl carboxyl or diC 1- One or more substituents in the 8-alkylamino group are substituted; Preferably, ring C is selected from C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 The aryl group or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 Aryl or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, optionally coated with a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1-6 Alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; More preferably, ring C is selected from C 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-14 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-14 membered heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group, etc. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted; More preferably, ring C is selected from C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-8 membered mono-heteroaryl containing 1-3 N, O or S atoms, or 8-14 membered fused heteroaryl containing 1-4 N, O or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted; More preferably, ring C is selected from C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-13 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-6 membered mono-heteroaryl containing 1-3 N, O or S atoms, or 8-13 membered fused heteroaryl containing 1-4 N, O or S atoms, optionally prefixed with an oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted; More preferably, the ring C is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. Furthermore, preferably, ring C is selected from... It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl, optionally covered by halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, alkenyl, ynyl, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents in the aryl or 3-14 heteroaryl groups are used for substitution; R6 is selected from halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally covered by halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; Alternatively, R6 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally replaced by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1- 8-alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl or C 1-8 One or more substituents in a cyano-substituted alkyl group are substituted; Alternatively, R6 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally replaced by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1- 8-alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl or C 1-8 One or more substituents in a cyano-substituted alkyl group are substituted; Preferably, R6 is selected from halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted to halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6- 12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution; Alternatively, R6 and R2 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, R6 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; More preferably, R6 is selected from halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, R6 and R2 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; Alternatively, R6 and R4 form C with the adjacent atoms. 3-5 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-15 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; More preferably, R6 is selected from fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, etc. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. Alternatively, R6 and R2 form with the adjacent atoms. It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; Alternatively, R6 and R4 form with the adjacent atoms It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; R7 or R8 are each independently selected from halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally covered by halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, alkenyl, ynyl, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; Alternatively, when v is 2, the two R8 atoms form a heterocyclic or heteroaryl group with the adjacent atom, wherein the heterocyclic or heteroaryl group is optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl or C 1-8 One or more substituents in a cyano-substituted alkyl group are substituted; Preferably, R7 or R8 is independently selected from halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1-6 Alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl acyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted to halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Alternatively, when v is 2, the two R8 atoms and the adjacent atoms form a 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or a 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms. The 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or the 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1- 6-alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; More preferably, R7 or R8 is independently selected from halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino, hydroxyl, C 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with a halogen, amino, hydroxyl, oxo, cyano, nitro, or C group. 1-3 Alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1- 3-hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, when v is 2, the two R8 atoms and the adjacent atoms form a 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms or a 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms. The 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms or the 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo group, or C. 1-3 One or more substituents in the alkyl group are substituted; More preferably, R7 or R8 is each independently selected from fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, wherein the amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, optionally substituted by one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl; Alternatively, when v is 2, two R8 atoms form with adjacent atoms. It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; s is 0, 1, or 2; r can be 0, 1, 2, or 3; v is 0, 1, or 2; m1 can be 0, 1, 2, or 3; n3 is either 0 or 1; The definitions of R2, R3, x, and y are as described in claim 2.

5. The compound or a pharmaceutically acceptable salt thereof according to claim 3 or 4, characterized in that, Wherein, general formula (II-1) is further shown as general formula (III-1), general formula (II-2) is further shown as general formula (III-2), and general formula (II-3) is further shown as general formula (III-3): The definitions of R2, R3, Y1, Y2, Y3, Y4, Y5, y, and z are as described in claim 1; the definitions of ring C, ring D, R6, R7, R8, R9, M1, M2, M4, M5, M6, s, v, r, and w are as described in claim 3.

6. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, characterized in that, Wherein, general formula (III-1) is further shown as general formula (IV-1), general formula (III-2) is further shown as general formula (IV-2), and general formula (III-3) is further shown as general formula (IV-3): The definitions of R3Y1, Y2, Y3, Y4, Y5 and z are as described in claim 1; the definitions of ring C, ring D, R6, R7, R8, R9, M1, M2, M4, M5, M6, s, v, r and w are as described in claim 3. Preferably, the general formula (IV-1) is further shown as general formula (V-1) or (V-2), the general formula (IV-2) is further shown as general formula (V-3) or (V-4), and the general formula (IV-3) is further shown as general formula (V-5) or (V-6): The definitions of R3, Y1, Y2, Y3, Y4, Y5 and z are as described in claim 1; the definitions of ring C, ring D, R6, R7, R8, R9, s, v, r and w are as described in claim 3.

7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, Wherein, general formula (I-1) is further shown as general formula (II-4), (II-5) or (II-6): in: Selected from M1 is selected from N or C; M2, M3, or M4 are each independently selected from N or CH; M6 or M5 are each independently selected from N, NH, CH or C(O); L3 is selected from -O(CR) 11 R 12 ) m1 -、-(CR 11 R 12 ) m1 -、-C(O)NR 13 -、-NR 13 C(O)- or -NR 14 -; preferably -O-, -OCH2-, -CH2-, -NHC(O)-, -C(O)NH-, -NH- or -N(CH3-), more preferably -O- or -OCH2-; Z1 is selected from C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Hydroxyalkyl or C 1- 8-Cyanosubstituted alkyl groups; Ring D is selected from cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1- 8-cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; Alternatively, R6 and R2 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally replaced by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, R6 and R4 form a cycloalkyl or heterocyclic group with the attached atom, wherein the cycloalkyl or heterocyclic group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; Alternatively, the two R6 groups form a cycloalkyl, heterocyclic, aryl, or heteroaryl group with the attached atom, wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; R8 groups are independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1- 8-cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, hydroxyl, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1- 8-alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 1-8 Alkyl acyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1- 8-Haloalkoxy, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; Alternatively, the two R8 atoms form a heterocyclic or heteroaryl group with the adjacent atom, wherein the heterocyclic or heteroaryl group is optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl groups or -(CH2) n1 C(O)(CH2) n2 R aa One or more substituents are substituted in the sample; R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1- 8-Haloalkoxy, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl or 3-14 heteroaryl groups, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents in the aryl or 3-14 heteroaryl groups are used for substitution; R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, and C. 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2- 8-olefin, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, wherein the amino, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 aryl, 3-14 heteroaryl or carboxyl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-8 Alkyl, C 1-8 Deuterated alkyl, C 2-8 alkenyl, C 2-8 alkynyl group, C 1-8 Haloalkyl, C 1-8 Haloalkenyl, C 1-8 Alkoxy, C 1-8 Halogenated alkoxy groups, C 1-8 Hydroxyalkyl, C 1-8 Cyano-substituted alkyl, C 3-14 Cycloalkyl, 3-14 membered heterocyclic groups, C 6-14 One or more substituents of aryl, 3-14 heteroaryl or carboxyl groups are used for substitution; s is 0, 1, or 2; w can be 0, 1, 2, 3, or 4; v is 0, 1, or 2; m1 can be 0, 1, 2, or 3; n3 is either 0 or 1; R2, R3, R 11 R 12 R aa The definitions of Y1, Y2, Y3, Y4, Y5, y, z, n1, and n2 are as described in claim 1.

8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof, characterized in that, Wherein, general formula (II-4) is further shown as general formula (III-4), general formula (II-5) is further shown as general formula (III-5), and general formula (II-6) is further shown as general formula (III-6): in: Z1 is selected from C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl or C 1- 6-Cyanosubstituted alkyl groups; Preferably, Z1 is selected from C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl or C 1-3 Cyano-substituted alkyl groups; More preferably, Z1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, or trifluoroethyl. More preferably, Z1 is selected from isopropyl; The definitions of R2, R3, Y1, Y2, Y3, Y4, Y5, y, and z are as described in claim 1; the definitions of rings D, R6, R8, R9, M1, M2, M4, M5, M6, s, v, and w are as described in claim 7.

9. The compound according to claim 8 or a pharmaceutically acceptable salt thereof, characterized in that, Wherein, general formula (III-4) is further shown as general formula (IV-4), general formula (III-5) is further shown as general formula (IV-5), and general formula (III-6) is further shown as general formula (IV-6): Wherein, R3, Y1, Y2, Y3, Y4, Y5 and z are defined as described in claim 1; rings D, R6, R8, R9, M1, M2, M4, M5, M6, s, v and w are defined as described in claim 7; Z1 is defined as described in claim 8; Preferably, the general formula (IV-4) is further shown as general formula (V-7) or (V-8), the general formula (IV-5) is further shown as general formula (V-9) or (V-10), and the general formula (IV-6) is further shown as general formula (V-11) or (V-12): The definitions of R3, Y1, Y2, Y3, Y4, Y5 and z are as described in claim 1; the definitions of rings D, R6, R8, R9, M1, M2, M4, M5, M6, s, v and w are as described in claim 7.

10. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that, Ring A is selected from C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 The aryl group or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 Aryl or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3- 12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 heteroaryl, carboxyl, dicarboxyl 1-6 Alkylamino or -(CH2) n1 O(CH2) n2 R aa One or more substituents are substituted in the sample; Preferably, ring A is selected from C. 3-10 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-12 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-12 heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, or C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 aryl, 5-12 membered heteroaryl containing 1-3 N, O or S atoms, carboxyl, dicarbonyl 1-3 Alkylamino or -(CH2) n1 O(CH2) n2 R aa One or more substituents are substituted in the sample; More preferably, ring A is selected from C. 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-12 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-12 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-5 N, O, or S atoms, or 8-12 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 6-12 Aryl, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, carboxyl, dicarbonyl 1-3 Alkylamino or -(CH2) n1 O(CH2) n2 R aa One or more substituents are substituted in the sample; More preferably, ring A is selected from C. 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-11 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-10 member fused heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-10 membered fused-heteroaryl containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 6-12 Aryl, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered fused heterocyclic groups containing 1-3 N, O, or S atoms, carboxyl, dicarbonyl 1-3 Alkylamino or -(CH2) n1 OR aa One or more substituents are substituted in the sample; More preferably, ring A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ... Optional radicals include hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, carboxyl, dimethylamino, and -CD3. One or more substituents are substituted in the sample; More preferably, ring A is selected from Optional radicals include hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, carboxyl, dimethylamino, and -CD3. One or more substituents are substituted in which This indicates that ring A is connected to L2; Alternatively, ring A does not exist.

11. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 2-6, characterized in that, Ring C is selected from C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 The aryl group or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 Aryl or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1- 6-alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Preferably, ring C is selected from C 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-14 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-14 membered heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted; More preferably, ring C is selected from C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-14 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted; More preferably, ring C is selected from C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-13 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, a 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or an 8-13 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 1-3 One or more substituents in the alkyl acyl or carboxyl group are substituted; More preferably, the ring C is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. More preferably, ring C is selected from... It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. More preferably, ring C is selected from... It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

12. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 2-9, characterized in that, Ring D is selected from C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 The aryl group or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-14 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-14 Aryl or containing 1-5 5-14 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3- 12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Preferably, ring D is selected from C. 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 Aryl or 5-14 heteroaryl containing 1-5 N, O or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-14 membered heterocyclic groups containing 1-5 N, O or S atoms, C 6-12 A aryl group or a 5-14 membered heteroaryl group containing 1-5 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1- 3-Hydroalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted; More preferably, ring D is selected from C. 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-8 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or 8-14 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C group. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted; More preferably, ring D is selected from C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, 5-6 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-13 member fused heteroaryl containing 1-4 N, O or S atoms, wherein the C 3-6 Monocycloalkyl, C 6-10 Polycyclic alkyl, C 5-8 Spirocycloalkyl, C 6-10 Bridged cycloalkyl groups, 3-6 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 6-13 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-8 membered spirocyclic groups containing 1-3 N, O, or S atoms, 6-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl, a 5-6 membered mono-heteroaryl containing 1-3 N, O, or S atoms, or an 8-13 membered fused heteroaryl containing 1-4 N, O, or S atoms, optionally prefixed with hydrogen, deuterium, oxo group, halogen, amino group, hydroxyl group, cyano group, nitro group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- One or more substituents in the alkyl or carboxyl group are substituted; More preferably, ring D is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. More preferably, ring D is selected from... It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

13. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that, L1 or L2 are each independently selected from the bond, -C(O)-, -(CR-). 11 R 12 ) m1 -、-O-、-S-、-C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - An aromatic heteroyl or heterocyclic group, wherein the aromatic heteroyl or heterocyclic group is optionally surrounded by an oxo group or a C-shaped group. 1-6 Alkyl, C2 1-6 alkenyl, C 2-6 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl, wherein the amino group, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally surrounded by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, or C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 The aryl group, a 5-12 membered heteroaryl group, or a carboxyl group is substituted by one or more substituents. Preferably, L1 or L2 is independently selected from bond, -C(O)-, -(CR)-, etc. 11 R 12 ) m1 -、-O-、-S-、-C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-8 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-8 membered heterocyclic heterocyclic group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2-3 alkenyl, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted; R 11 R 12 R 13 Or R 14 Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl groups, including amino, hydroxyl, cyano, nitro, and C groups. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3 alkyl groups, optionally replaced by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 3-8 Monocycloalkyl, C 4-10 Polycyclic alkyl, C 5-10 Spirocycloalkyl, C 4-10 Bridged cycloalkyl groups, 3-8 membered monoheterocyclic groups containing 1-3 N, O, or S atoms, 4-14 membered fused heterocyclic groups containing 1-4 N, O, or S atoms, 5-10 membered spirocyclic groups containing 1-3 N, O, or S atoms, 4-10 membered bridged heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 It is substituted by one or more substituents, including aryl, 5-8 member monoheteroaryl containing 1-3 N, O or S atoms, or 8-14 member fused heteroaryl containing 1-4 N, O or S atoms; More preferably, L1 or L2 is independently selected from the bond, -C(O)-, and -CR. 11 R 12 -、-O-、-S-、-C(O)NR 13 -、-NR 13 C(O)-、-C(S)NR 13 -、-NR 13 C(S)-、-NR 14 - A 5-6 membered aromatic heteromethyl group containing 1-3 N, O, or S atoms, or a 3-6 membered heterocyclic heteromethyl group containing 1-3 N, O, or S atoms, wherein the aromatic heteromethyl group or heterocyclic heteromethyl group is optionally surrounded by an oxo group or a C group. 1-3 Alkyl, C 2- 3-olefin, C 2-3 Alkyne, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 One or more substituents in the alkyl or carboxyl group are substituted; R 11 R 12 R 13 Or R 14 Each of the following groups is independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl, wherein the amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, phenyl, benzyl, or naphthyl groups are optionally substituted by one or more substituents selected from hydroxyl, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, or trifluoroethyl groups; More preferably, L1 or L2 is independently selected from bonds, -C(O)-, -CH2-, -CH(CH3)-, -O-, -S-, -C(O)NH-, -NHC(O)-, -C(S)NH-, -NHC(S)-, The It may optionally be substituted by one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, or carboxyl.

14. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, characterized in that, R1 or R4 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-6 Alkyl, C 1- 6-Deuterated Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 membered heteroaryl, carboxyl, -(CH2) n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb -(CH2) n1 C(O)NR aa R bb Or -(CH2) n1 N=S(O)R aa R bb The amino, hydroxyl, thiol, and C groups mentioned above 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Alternatively, R1 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Or, R1, R 11 Forming C with the attached atoms 3-12 Cycloalkyl, 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14 membered heteroaryl groups containing 1-5 N, O, or S atoms, wherein the C 3-12 Cycloalkyl, 3-16-membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14-membered heteroaryl groups containing 1-5 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, two R1 atoms form C with the adjacent atoms. 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 The aryl group or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 Aryl or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1- 6-hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the aforementioned amino, hydroxyl, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 heteroaryl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Preferably, R1 or R4 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1- 3-alkoxy group, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-10 heteroaryl groups containing 1-3 N, O or S atoms, carboxyl, -OR aa -NR aa R bb -NR aa C(O)R bb -C(O)NR aa R bb Or -N = S(O)R aa R bb The amino, hydroxyl, thiol, and C groups mentioned above 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, R1 and R4 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, wherein the C 3-15 Cycloalkyl or containing 1-4 5-15 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; Or, R1, R 11 Forming C with the attached atoms 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered monoheteroaryl groups containing 1-3 N, O, or S atoms, wherein the C 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered mono-heteroaryl groups containing 1-3 N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 One or more substituents in the alkyl group are substituted; Alternatively, two R1 atoms form C with the adjacent atoms. 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 The aryl group or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 Aryl or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 Alkyl, Halogenated C 1-3 Alkoxy, C 1-3 Deuterated alkyl or C 1-3 One or more substituents in the deuterated alkoxy group are substituted; R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, and a carboxyl group, wherein the amino, hydroxyl, and C groups are present. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group is substituted with one or more substituents selected from 1-3 5-10 heteroaryl or carboxyl groups chosen from N, O or S atoms; More preferably, R aa Or R bb Each is independently selected from hydrogen, methyl, ethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. More preferably, R1 or R4 is independently selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -CD3, -OCD3, -SCH3, -OCF3, The groups mentioned are amino, methylamino, dimethylamino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3. It may be optionally substituted with one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. Alternatively, R1 and R4 form with the adjacent atoms It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; Or, R1, R 11 Forming with adjacent atoms It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; Alternatively, two R1 atoms form with the adjacent atoms. It may optionally be substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, carboxyl, -CD3, or -OCF3.

15. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-14, characterized in that, R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 membered heteroaryl, carboxyl, -(CH2) n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb -(CH2) n1 C(O)NR aa R bb Or -(CH2) n1 N=S(O)R aa R bb The amino, hydroxyl, thiol, and C groups mentioned above 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1- 6-alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Alternatively, R1 and R2 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, R2 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the aforementioned amino, hydroxyl, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 heteroaryl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Preferably, R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-10 heteroaryl groups containing 1-3 N, O or S atoms, carboxyl, -OR aa -NR aa R bb -NR aa C(O)R bb -C(O)NR aa R bb Or -N = S(O)R aa R bb The amino, hydroxyl, thiol, and C groups mentioned above 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, R1 and R2 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; Alternatively, R2 and R4 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, and a carboxyl group, wherein the amino, hydroxyl, and C groups are present. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group is substituted with one or more substituents selected from 1-3 5-10 heteroaryl or carboxyl groups chosen from N, O or S atoms; More preferably, R aa Or R bb Each is independently selected from hydrogen, methyl, ethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. More preferably, R2 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -CD3, -OCD3, -SCH3, -OCF3, The groups mentioned are amino, methylamino, dimethylamino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3. It may be optionally substituted with one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. Alternatively, R1 and R2 form with the adjacent atoms It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; Alternatively, R2 and R4 form with the adjacent atoms It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

16. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-15, characterized in that, R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 membered heteroaryl, carboxyl, -(CH2) n1 O(CH2) n2 R aa -(CH2) n1 NR aa (CH2) n2 R bb -(CH2) n1 NR aa C(O)R bb -(CH2) n1 C(O)NR aa R bb Or -(CH2) n1 N=S(O)R aa R bb The amino, hydroxyl, and C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6- 12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution; Alternatively, R3 and R4 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, two R3 atoms form C with the adjacent atoms. 3-12 Cycloalkyl, 3-16 membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14 membered heteroaryl groups containing 1-5 N, O, or S atoms, wherein the C 3-12 Cycloalkyl, 3-16-membered heterocyclic groups containing 1-6 N, O, or S atoms, or 5-14-membered heteroaryl groups containing 1-5 N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the aforementioned amino, hydroxyl, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl, 5-12 heteroaryl, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Preferably, R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2- 4-Alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, 5-10 heteroaryl groups containing 1-3 N, O or S atoms, carboxyl, -OR aa -NR aa R bb -NR aa C(O)R bb -C(O)NR aa R bb Or -N = S(O)R aa R bb The amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, R3 and R4 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or 5-10 membered heterocyclic group, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo group or C 1- One or more substituents in the 3 alkyl group are substituted; Alternatively, two R3 atoms form C with the adjacent atoms. 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered monoheteroaryl groups containing 1-3 N, O, or S atoms, wherein the C 3-10 Cycloalkyl, 5-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, or 5-6 membered mono-heteroaryl groups containing 1-3 N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 One or more substituents in the alkyl group are substituted; R aa Or R bb Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, and a carboxyl group, wherein the amino, hydroxyl, and C groups are present. 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group is substituted with one or more substituents selected from 1-3 5-10 heteroaryl or carboxyl groups chosen from N, O or S atoms; More preferably, R aa Or R bb Each is independently selected from hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, It may be optionally substituted with one or more of the following substituents: hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. More preferably, R3 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2, The groups mentioned are amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -N(CH3)2, Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. Alternatively, R3 and R4 form with the adjacent atoms It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; Alternatively, two R3 atoms form with the adjacent atoms. It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

17. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 2-9, characterized in that, R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 1- 6-Deuterated Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution; Alternatively, R6 and R2 form C with the adjacent atoms. 3-12 Cycloalkyl or containing 1-6 3-16 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl or 3-16 membered heterocyclic groups containing 1-6 N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1- 6-alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Alternatively, two R6 atoms form C with the adjacent atoms. 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 The aryl group or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-12 Cycloalkyl groups, 3-12 membered heterocyclic groups containing 1-5 N, O, or S atoms, C 6-12 Aryl or containing 1-5 5-12 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Deuterated alkoxy, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1- 6-hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Preferably, R6 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2- 4-Alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, R6 and R2 form C with the adjacent atoms. 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl or containing 1-4 5-10 membered heterocyclic groups selected from N, O or S atoms, optionally surrounded by hydrogen, halogen, amino, hydroxyl, oxo or C. 1-3 One or more substituents in the alkyl group are substituted; Alternatively, two R6 atoms form C with the adjacent atoms. 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 The aryl group or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, wherein the C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-4 N, O, or S atoms, C 6-10 Aryl or containing 1-4 5-10 heteroaryl groups selected from N, O, or S atoms, optionally coated with hydrogen, halogen, amino, hydroxyl, oxo, or C. 1-3 Alkyl, Halogenated C 1-3 Alkoxy, C 1-3 Deuterated alkyl or C 1-3 One or more substituents in the deuterated alkoxy group are substituted; More preferably, R6 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, etc. The amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, and other amino groups mentioned above. Optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. Alternatively, R6 and R2 form with the adjacent atoms. It may be optionally substituted with one or more substituents selected from hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl or isopropyl; Alternatively, two R6 atoms form with the adjacent atoms. It may optionally be substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, carboxyl, -CD3, or -OCF3.

18. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 2-6, characterized in that, R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1-6 Alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl or carboxyl, wherein the amino, hydroxyl, mercapto, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 Alkyl acyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Preferably, R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino, hydroxyl, mercapto, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1- 3-alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. More preferably, R7 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -CD3, -OCD3, -SCH3, -OCF3. The groups mentioned are amino, methylamino, dimethylamino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3. Optionally substituted by one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl.

19. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 2-9, characterized in that, R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 1-6 Alkyl acyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl or carboxyl, wherein the amino, hydroxyl, mercapto, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, C 1-6 Alkyl acyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkyl thiols, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents of aryl, 5-12 heteroaryl or carboxyl groups are used for substitution; Alternatively, the two R8 atoms form a 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or a 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms. The 3-12 membered heterocyclic group containing 1-3 N, O, or S atoms or the 5-12 membered heteroaryl group containing 1-3 N, O, or S atoms may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo, cyano, nitro, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl or cyano-substituted C 1-6 One or more substituents in the alkyl group are substituted; Preferably, R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O or S atoms, wherein the amino, hydroxyl, mercapto, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 1-3 Alkyl acyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, mercapto, oxo, cyano, nitro, C 1- 3-alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 1-3 Alkyl thiols, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. Alternatively, the two R8 atoms form a 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms, or a 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms. The 5-10 membered heterocyclic group containing 1-3 N, O, or S atoms, or the 5-6 membered monoheteroaryl group containing 1-3 N, O, or S atoms, may optionally be converted by hydrogen, halogen, amino, hydroxyl, oxo group, or C. 1-3 One or more substituents in the alkyl group are substituted; More preferably, R8 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, acetyl, -NHCH3, -NHCH2CH3, -CD3, -OCD3, -SCH3, -OCF3. The groups mentioned are amino, methylamino, dimethylamino, hydroxy, mercapto, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -NHCH3, -NHCH2CH3. Optionally substituted by one or more substituents of hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl, or carboxyl. Alternatively, two R8 atoms form with adjacent atoms. It may optionally be substituted with one or more of the following substituents: hydrogen, fluorine, chlorine, bromine, amino, hydroxyl, oxo, methyl, ethyl, or isopropyl.

20. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 2-9, characterized in that, R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, and C. 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 aryl, 5-12 heteroaryl, carboxyl, and the amino group, C 1-6 Alkyl, C 1- 6-Deuterated Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 Aryl or 5-12 heteroaryl groups, optionally further converted by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 2-6 alkenyl, C 1-6 hydroxyalkyl, cyano-substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic groups, C 6-12 One or more substituents in the aryl or 5-12 heteroaryl groups are used for substitution; Preferably, R9 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2- 4-Alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1- 3-alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 aryl, containing 1-3 5-10 heteroaryl or carboxyl groups selected from N, O, or S atoms, wherein the amino group, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 Aryl or containing 1-3 5-10 heteroaryl groups selected from N, O, or S atoms, optionally surrounded by hydrogen, deuterium, halogen, amino, hydroxyl, oxo, cyano, nitro, C 1-3 Alkyl, C 1-3 Deuterated alkyl, C 2-4 alkenyl, C 2-4 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 hydroxyalkyl, cyano-substituted C 1-3 Alkyl, C 3-10 Cycloalkyl groups, 3-10 membered heterocyclic groups containing 1-3 N, O, or S atoms, C 6-10 The aryl group or one or more substituents selected from 1-3 5-10 heteroaryl groups chosen from N, O or S atoms are used for substitution. More preferably, R9 is selected from hydrogen, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, -CD3 or -OCF3, wherein the amino, methylamino, dimethylamino, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy or propoxy, optionally substituted by one or more substituents selected from hydrogen, oxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, acetyl or carboxyl.

21. The following compounds, or their pharmaceutically acceptable salts, have the following specific structures:

22. A compound of general formula (M-1) or (M-2) or a pharmaceutically acceptable salt thereof: in: P1 is selected from hydrogen or an amino protecting group; Preferably, the amino protecting group is selected from allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, triphenylmethyl, fluorenylmethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butyloxycarbonyl, benzyl or p-toluoxy; more preferably 2,4-dimethoxybenzyl or tert-butyloxycarbonyl. In general formula (M-1), X1, X2, X3, X4, X5, R2, R3, y, and z are defined as described in claim 1; rings C, R7, R8, M1, M2, M4, M5, M6, v, and r are defined as described in claim 5. In general formula (M-2), X1, X2, X3, X4, X5, R2, R3, y and z are defined as described in claim 1; rings C, R8, M1, M2, M4, M5, M6, v and Z1 are defined as described in claim 8.

23. A method for preparing the compound as described in claim 5 or 8, or a pharmaceutically acceptable salt thereof, characterized in that, It includes the following steps: Deprotection of general formula (M-1A) yields a compound of general formula (M-1B) or a pharmaceutically acceptable salt thereof; then, general formula (M-1B) undergoes a condensation reaction with general formula (M-3) to yield a compound of general formula (III-1) or a pharmaceutically acceptable salt thereof. in, Pg is selected from amino protecting groups, preferably allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, triphenylmethyl, fluorenylmethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butyloxycarbonyl, benzyl or p-toluoxy; more preferably 2,4-dimethoxybenzyl or tert-butyloxycarbonyl. R is selected from halogen, hydroxyl group, or -C(O)OR A The preferred elements are fluorine, chlorine, bromine, iodine, or hydroxyl; more preferably, chlorine or hydroxyl. R A Selected from C 1-6 alkyl; The definitions of X1, X2, X3, X4, X5, R2, R3, y, and z are as described in claim 1; the definitions of rings C, R6, R7, R8, M1, M2, M4, M5, M6, s, v, and r are as described in claim 5; Alternatively, it may include the following steps: Deprotection of general formula (M-2A) yields a compound of general formula (M-2B) or a pharmaceutically acceptable salt thereof; then, general formula (M-2B) undergoes a condensation reaction with general formula (M-3) to yield a compound of general formula (III-4) or a pharmaceutically acceptable salt thereof; in, Pg is selected from amino protecting groups, preferably allyloxycarbonyl, trifluoroacetyl, 2,4-dimethoxybenzyl, nitrobenzenesulfonyl, triphenylmethyl, fluorenylmethoxycarbonyl, p-toluenesulfonyl, formate, acetyl, benzyloxycarbonyl, tert-butyloxycarbonyl, benzyl or p-toluoxy; more preferably 2,4-dimethoxybenzyl or tert-butyloxycarbonyl. R is selected from halogen, hydroxyl group, or -C(O)OR A The preferred elements are fluorine, chlorine, bromine, iodine, or hydroxyl; more preferably, chlorine or hydroxyl. R A Selected from C 1-6 alkyl; The definitions of X1, X2, X3, X4, X5, R2, R3, y, and z are as described in claim 1; the definitions of R6, R8, M1, M2, M4, M5, M6, s, v, and Z1 are as described in claim 8.

24. A pharmaceutical composition comprising a therapeutically effective dose of the compound of claims 1-21 and its stereoisomers or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers or excipients.

25. The use of the compound, stereoisomer, or pharmaceutically acceptable salt thereof, according to any one of claims 1-21, in the preparation of NK inhibitor-related drugs, preferably in the preparation of NK3 inhibitor-related drugs.

26. The use of any compound according to any one of claims 1-21, its stereoisomers or pharmaceutically acceptable salts thereof, or the pharmaceutical composition according to claim 24 in the preparation of a medicament for the treatment and / or prevention of psychotic disorders, cognitive impairment, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, seizures, obesity, inflammatory diseases, vomiting, preeclampsia, airway-related diseases, reproductive disorders, sex hormone-dependent diseases or gynecological diseases.

27. The use of any compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof, according to any one of claims 1-21, in the preparation of a medicament for the treatment and / or prevention of menopausal syndrome, polycystic ovary syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor syndrome, or breast cancer-related diseases, wherein the menopausal syndrome includes symptoms such as hot flashes, sweating, palpitations, dizziness, or obesity.

Images